

CURRICULUM VITAE

Date of Revision: June 26, 2019
Name: Alexandra Lansky, MD, FACC, FAHA, FSCAI, FESC
School: Yale School of Medicine

Education:

BS, College of William and Mary 1986
MD, Medical College of Virginia, Richmond, Virginia 1990

Career/Academic Appointments:

1991 - 1993 Residency, Internal Medicine, Washington Hospital Center, Washington, DC
1993 - 1997 Fellowship, Cardiovascular Disease, Washington Hospital Center, Washington, DC
1996 - 1997 Fellowship, Interventional Cardiology, Washington Hospital Center, Washington, DC
2010 Instructor, Cardiology (Medicine), Yale School of Medicine, New Haven, CT
2010 - 2015 Associate Professor on Term, Cardiology (Medicine), Yale School of Medicine, New Haven, CT
2015 - present Professor, Cardiology (Medicine), Yale School of Medicine, New Haven, CT

Administrative Positions:

2010 - present Director, Cardiology, Yale University School of Medicine, New Haven, CT
2017 - present Director of Yale UCLP Clinical Research Program Yale University School of Medicine, New Haven, CT, The Barts Heart Center and Queen Mary University of London, Cardiology, The Barts Heart Center and Queen Mary University of London, London, England, United Kingdom

Board Certification:

AB of Internal Medicine, Cardiovascular Disease, 11-2002

Professional Honors & Recognition:

International/National/Regional

2018 Visiting Professor, Chinese PLA General Hospital, Beijing China
2016 Thompson Reuter's 2016 Web of Science Highly Cited Researcher
2014 Thompson Reuter's 2014 Worlds Most Influential Scientific Minds for Clinical Medicine
2012 Wender Award of Excellence in Women's Health Care. WomenHeart: the National Coalition of Women with Heart Disease awarded the annual Wenger Award for Excellence in Women's Health Care, for excellence in medical leadership, and a life long commitment to pursuing gender-based outcomes research

2012	Visiting Professor of Cardiology; Fu Wai Hospital, National Center for Cardiovascular Diseases of China, Beijing, China
1996	Dihllon Fellow Award
1995	ACC / Bristol Myers Squibb Affiliate Travel Award
1994	AHA / ACC Genentech Grant Award
1993	American Heart Association, Nation's Capital Affiliate Research

University

2017	YMG Scholarship: Advanced Emerging Leaders Program, Yale School of Management
2017	M.A. privatim, Yale University (Honorary Masters of Arts)
2016	YMG Scholarship: Emerging Leaders Program, Yale School of Management

Yale School Of Medicine

2017	Scholarship Yale Department of Medicine: American Academy on Communication in
------	---

Grants/Clinical Trials History:

Current Grants

Agency:	Merit Medical
I.D.#:	19-005915
Title:	Wrapsody First Iliac
Role:	Principal Investigator
Percent effort:	1%
Direct costs per year:	\$21,440.00
Total costs for project period:	\$24,656.00
Project period:	6/13/2019 - 6/13/2024

Agency:	TriReme
I.D.#:	19-005893
Title:	Chocolate Touch DSMB
Role:	Principal Investigator
Percent effort:	1%
Direct costs per year:	\$43,950.00
Total costs for project period:	\$50,542.50
Project period:	6/11/2019 - 6/11/2024

Agency:	Sano V
I.D.#:	19-005854
Title:	N-Finity Refunction CEC
Role:	Principal Investigator
Percent effort:	1%

Direct costs per year: \$9,500.87
 Total costs for project period: \$10,926.00
 Project period: 6/10/2019 - 6/10/2024

Agency: IHF GmbH
 I.D.#: 19-005832
 Title: Reboot Paradox
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$175,605.00
 Total costs for project period: \$201,945.75
 Project period: 6/7/2019 - 6/7/2024

Agency: Lifetech
 I.D.#: 19-005778
 Title: Clinical Trial Protocol Revision and Sample Size Justification
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$46,750.00
 Total costs for project period: \$53,762.50
 Project period: 6/5/2019 - 6/5/2024

Agency: Vascular Solutions
 I.D.#: 19-005402
 Title: CTO-PCI
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$101,250.00
 Total costs for project period: \$116,437.50
 Project period: 5/29/2019 - 5/28/2024

Agency: W.L Gore
 I.D.#: 19-005169
 Title: GSO 17-03
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$72,760.87
 Total costs for project period: \$83,675.00
 Project period: 4/15/2019 - 4/14/2024

Agency: Keystone Heart
 I.D.#: 19-005481
 Title: Literature Review 4.0
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$14,885.00
 Total costs for project period: \$17,117.75
 Project period: 4/1/2019 - 3/31/2024

Agency: TriReme
 I.D.#: 19-004721
 Title: Chocolate Touch BTK IDE Design
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$22,300.00
 Total costs for project period: \$25,645.00
 Project period: 3/1/2019 - 2/29/2024

Agency: Corindus
 I.D.#: 19-004124
 Title: Japan PMS Study
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$141,890.43
 Total costs for project period: \$163,174.00
 Project period: 2/11/2019 - 2/10/2024

Agency: Keystone Heart
 I.D.#: 19-004213
 Title: Reflect Phase II CEC
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$698,425.00
 Total costs for project period: \$803,188.75
 Project period: 2/1/2019 - 1/31/2024

Agency: Bard
 I.D.#: 19-003552
 Title: Lutonix SFA Confirmatory IDE

Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$67,300.00
 Total costs for project period: \$77,395.00
 Project period: 1/18/2019 - 1/17/2024

Agency: Keystone Heart
 I.D.#: 19-003654
 Title: Utrecht CSR and SAE
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$6,850.00
 Total costs for project period: \$7,877.50
 Project period: 1/1/2019 - 12/31/2024

Agency: Eidos
 I.D.#: 19-003339
 Title: AG10-301
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$257,008.53
 Total costs for project period: \$295,559.81
 Project period: 12/15/2018 - 12/14/2023

Agency: Ablative Solutions
 I.D.#: 19-003271
 Title: Target BP I CEC/DSMB
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$168,800.00
 Total costs for project period: \$194,120.00
 Project period: 12/11/2018 - 12/10/2023

Agency: Surmodics
 I.D.#: 19-002875
 Title: Avers
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$33,900.00
 Total costs for project

period: \$38,985.00
Project period: 11/1/2018 - 11/1/2023

Agency: Keystone Heart
I.D.#: 19-003343
Title: EU PMS CIP Triguard 3
Role: Principal Investigator
Percent effort: 1%
Direct costs per year: \$13,300.00
Total costs for project
period: \$15,295.00
Project period: 11/1/2018 - 10/30/2023

Agency: Cormatrix
I.D.#: 19-003541
Title: Tricuspid ECM Valve Replacements EFS
Role: Principal Investigator
Percent effort: 1%
Direct costs per year: \$47,575.00
Total costs for project
period: \$54,711.25
Project period: 11/1/2018 - 11/30/2023

Agency: Angiosafe
I.D.#: 19-002709
Title: Panama Coronary
Role: Principal Investigator
Percent effort: 1%
Direct costs per year: \$41,900.00
Total costs for project
period: \$48,185.00
Project period: 10/1/2018 - 10/1/2023

Agency: Angiosafe
I.D.#: 19-002711
Title: Panama Peripheral
Role: Principal Investigator
Percent effort: 1%
Direct costs per year: \$52,650.00
Total costs for project
period: \$60,547.50
Project period: 10/1/2018 - 10/1/2023

Agency: PQ Bypass

I.D.#: 19-002243
 Title: Literature Review
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$13,500.00
 Total costs for project period: \$15,525.00
 Project period: 9/15/2018 - 9/14/2023

Agency: W.L Gore
 I.D.#: 19-001803
 Title: GSO 18-01
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$953,086.96
 Total costs for project period: \$1,096,050.00
 Project period: 9/1/2018 - 9/1/2023

Agency: Bard
 I.D.#: 19-001718
 Title: Bolster China
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$151,614.78
 Total costs for project period: \$174,357.00
 Project period: 8/1/2018 - 8/1/2020

Agency: Medtronic
 I.D.#: 18-006055
 Title: CABG Registry
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$69,565.22
 Total costs for project period: \$80,000.00
 Project period: 6/25/2018 - 6/24/2023

Agency: Conformal
 I.D.#: 18-005623
 Title: CLAAS Early Feasibility
 Role: Principal Investigator
 Percent effort: 1%

Direct costs per year: \$133,650.00
 Total costs for project period: \$153,697.50
 Project period: 6/1/2018 - 5/31/2023

Agency: Contego Medical
 I.D.#: 18-005937
 Title: Performance I
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$42,241.50
 Total costs for project period: \$48,577.73
 Project period: 6/1/2018 - 6/1/2022

Agency: W.L. Gore
 I.D.#: 18-005849
 Title: HRT
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$193,199.65
 Total costs for project period: \$222,179.60
 Project period: 5/18/2018 - 5/17/2020

Agency: Ablative Solutions
 I.D.#: 18-005343
 Title: CEC/DSMB
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$67,275.00
 Total costs for project period: \$77,366.25
 Project period: 5/1/2018 - 4/30/2021

Agency: KeyStone Heart
 I.D.#: 18-004937
 Title: Reflect Phase II DSMB
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$138,800.00
 Total costs for project period: \$159,620.00
 Project period: 4/1/2018 - 4/1/2022

Agency: Cardiatis
 I.D.#: 18-005096
 Title: Literature Review EFS Indication
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$24,225.00
 Total costs for project period: \$27,858.75
 Project period: 4/1/2018 - 3/31/2020

Agency: Abbott
 I.D.#: 18-005854
 Title: Amplatz PIVSD
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$29,035.65
 Total costs for project period: \$33,391.00
 Project period: 4/1/2018 - 4/1/2022

Agency: Bard
 I.D.#: 18-004134
 Title: AV Post Approval
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$100,855.00
 Total costs for project period: \$115,983.25
 Project period: 2/12/2018 - 2/12/2022

Agency: TriReme
 I.D.#: 18-003927
 Title: Chocolate Heart US IDE – Initial Clinical and Regulatory Strategy Consulting
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$86,450.00
 Total costs for project period: \$99,417.50
 Project period: 2/1/2018 - 2/1/2022

Agency: Abiomed
 I.D.#: 18-003934
 Title: cVAD

Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$62,050.00
 Total costs for project period: \$71,357.50
 Project period: 1/1/2018 - 1/1/2023

Agency: Keystone Heart
 I.D.#: 18-003937
 Title: Literature Review
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$29,730.00
 Total costs for project period: \$34,189.50
 Project period: 1/1/2018 - 1/1/2022

Agency: W.L. Gore
 I.D.#: 18-003398
 Title: MVRx Maveric
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$153,854.78
 Total costs for project period: \$176,933.00
 Project period: 12/1/2017 - 12/1/2021

Agency: Shockwave Medical
 I.D.#: 18-003400
 Title: Shockwave CAD II
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$129,250.00
 Total costs for project period: \$148,637.50
 Project period: 12/1/2017 - 12/1/2022

Agency: Keystone Heart
 I.D.#: 18-002350
 Title: TriGuard 3
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$260,300.00
 Total costs for project

period: \$299,345.00
Project period: 11/1/2017 - 11/1/2022

Agency: SinoMed
I.D.#: 18-003037
Title: Reduce DAPT
Role: Principal Investigator
Percent effort: 1%
Direct costs per year: \$327,025.00
Total costs for project period: \$376,078.75
Project period: 11/1/2017 - 10/31/2022

Agency: Angiosafe
I.D.#: 18-001359
Title: Coronary and Peripheral
Role: Principal Investigator
Percent effort: 1%
Direct costs per year: \$82,975.00
Total costs for project period: \$95,421.25
Project period: 10/1/2017 - 9/30/2022

Agency: PhaseBio Pharmaceuticals Inc.
I.D.#: 18-002276
Title: PhaseBio DSMB
Role: Principal Investigator
Percent effort: 1%
Direct costs per year: \$68,350.00
Total costs for project period: \$78,602.50
Project period: 10/1/2017 - 10/1/2022

Agency: W.L. Gore
I.D.#: 18-002343
Title: PV1
Role: Principal Investigator
Percent effort: 1%
Direct costs per year: \$84,403.48
Total costs for project period: \$97,064.00
Project period: 10/1/2017 - 10/1/2022

Agency: LimFlow SA

I.D.#: 18-001535
 Title: Lim Flow Literature Review
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$25,650.00
 Total costs for project period: \$29,497.50
 Project period: 9/1/2017 - 8/31/2021

Agency: SurModics
 I.D.#: 18-001539
 Title: SurVeil Drug Coated Balloon (SUR 17-001)
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$235,884.57
 Total costs for project period: \$271,267.25
 Project period: 9/1/2017 - 8/31/2021

Agency: REVA Medical
 I.D.#: 18-002032
 Title: Fantom Literature Review
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$22,500.00
 Total costs for project period: \$25,875.00
 Project period: 9/1/2017 - 8/31/2022

Agency: TriReme
 I.D.#: 18-002345
 Title: Chocolate Heart US IDE
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$6,325.00
 Total costs for project period: \$7,273.75
 Project period: 9/1/2017 - 9/1/2022

Agency: Intact Vascular
 I.D.#: 18-002357
 Title: TOBA II & III
 Role: Principal Investigator
 Percent effort: 1%

Direct costs per year: \$190,746.52
 Total costs for project period: \$219,358.50
 Project period: 9/1/2017 - 9/1/2022

Agency: Svelte Medical Systems
 I.D.#: 18-001537
 Title: Svelte Optimize
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$422,894.13
 Total costs for project period: \$486,328.25
 Project period: 8/1/2017 - 8/31/2021

Agency: ReFlow Medical
 I.D.#: 18-001433
 Title: Wing It RFM CTO 13001
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$83,302.61
 Total costs for project period: \$95,798.00
 Project period: 7/21/2017 - 6/30/2021

Agency: Cedars - Sinai Medical Center
 I.D.#: 17-005970
 Title: Cedars Sinai Heart Institute Alpha PAH
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$124,115.00
 Total costs for project period: \$142,732.25
 Project period: 6/1/2017 - 5/31/2022

Agency: Shockwave medical
 I.D.#: 18-001010
 Title: Shockwave PAD 2 CEC
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$30,060.00
 Total costs for project period: \$34,569.00
 Project period: 6/1/2017 - 5/31/2021

Agency: BioMedical Research Center Grant, National institute for Health Research, UK
 I.D.#: 17-004353
 Title: Device Innovation Theme, Bart's Heart Center
 Role: Principal Investigator
 Percent effort: 2%
 Direct costs per year: \$6,624,126.00
 Total costs for project period: \$7,617,745.00
 Project period: 4/1/2017 - 4/1/2022

Agency: REVA Medical, Inc
 I.D.#: Fantom
 Title: Prospective randomized, single-blind, multi-center, controlled clinical trial
 Role: Principal Investigator
 Percent effort: 2%
 Direct costs per year: \$1,198,775.00
 Total costs for project period: \$1,378,591.25
 Project period: 3/1/2017 - 2/28/2022

Agency: St Jude Medical
 I.D.#: Abbot Portico I
 Title: Portico I Study: International Long Term Follow-Up Study of Patients Implanted with a PORTICO Valve
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$79,867.00
 Total costs for project period: \$918,470.50
 Project period: 3/1/2017 - 2/28/2022

Agency: St Jude Medical
 I.D.#: Abbot Portico ALT
 Title: Portico ALT: Assessment of the St Jude Medical Portico Re-sheathable Aortic Valve System – Alternative Access
 Role: Principal Investigator
 Percent effort: 5%
 Direct costs per year: \$206,300.00
 Total costs for project period: \$237,245.00
 Project period: 3/1/2017 - 2/28/2022

Agency: St Jude Medical

I.D.#: Abbot Trifecta GT
 Title: Trifecta GT Post Market Clinical Follow-up
 Role: Principal Investigator
 Percent effort: 5%
 Direct costs per year: \$527,400.00
 Total costs for project period: \$606,510.00
 Project period: 3/1/2017 - 2/28/2022

Agency: Abiomed
 I.D.#: 17-004377
 Title: Impella CP Echo
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$28,760.87
 Total costs for project period: \$33,075.00
 Project period: 2/2/2017 - 1/31/2022

Agency: Svelte Medical Systems, Inc
 I.D.#: Svelte Optimize
 Title: The DIRECT IV IDE Study: Direct Implantation of Sirolimus-Eluting Stents with Bioreasorbable Drug Carrier Technology Utilizing the Svelte Drug-Eluting Coronary Stent
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$370,556.00
 Total costs for project period: \$426,139.55
 Project period: 2/1/2017 - 2/1/2022

Agency: W.L. Gore & Associates, Inc.
 I.D.#: 18-001538
 Title: Evaluation of GORE TIGRIS Vascular Stent in the Treatment of Restenotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$26,250.00
 Total costs for project period: \$30,187.00
 Project period: 2/1/2017 - 1/31/2022

Agency: Micell Technologies
 I.D.#: Micell Mistent

Title:	A Prospective Multi-Center, Randomized, Controlled Trial to Demonstrate the Safety and Effectiveness of the MiStent Sirolimus Eluting Stent System for the revascularization of coronary arteries
Role:	Principal Investigator
Percent effort:	2%
Direct costs per year:	\$563,650.00
Total costs for project period:	\$648,198.00
Project period:	1/1/2017 - 12/31/2022
Agency:	TriReme Medical
I.D.#:	17-002762
Title:	The Control Study: Chocolate PTCA Balloon Catheter for Treatment of Coronary Artery Lesions, A Post Market Study
Role:	Principal Investigator
Percent effort:	3%
Direct costs per year:	\$60,788.00
Total costs for project period:	\$69,905.63
Project period:	1/1/2017 - 12/31/2022
Agency:	TriReme Medical
I.D.#:	16-005466
Title:	The Chocolate Touch Study: A Randomized Assessment to confirm the Safety and Effectiveness of Chocolate Touch, the Paclitaxel Drug Coated Chocolate PTA Balloon Catheter, in Above the Knee Lesions
Role:	Principal Investigator
Percent effort:	3%
Direct costs per year:	\$302,030.00
Total costs for project period:	\$347,334.50
Project period:	1/1/2017 - 12/31/2022
Agency:	Abbott
I.D.#:	17-004169
Title:	Trifecta GT
Role:	Principal Investigator
Percent effort:	1%
Direct costs per year:	\$527,400.00
Total costs for project period:	\$606,510.00
Project period:	1/1/2017 - 12/31/2021
Agency:	Abiomed

I.D.#: 17-004171
 Title: Impella CP ECG
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$23,337.50
 Total costs for project period: \$26,838.13
 Project period: 1/1/2017 - 12/31/2021

Agency: Abiomed, Inc.
 I.D.#: 17-004171
 Title: Door to Unloading with IMPELLA CP® System in Acute Myocardial Infarction to Reduce Infarct Size (DTU): A Prospective Feasibility Study
 Role: Principal Investigator
 Percent effort: 5%
 Direct costs per year: \$23,337.00
 Total costs for project period: \$26,838.30
 Project period: 12/20/2016 - 12/19/2021

Agency: Shockwave Medical
 I.D.#: 17-003397
 Title: Randomized Study of the Shockwave Medical Peripheral Lithoplasty System followed by drug-coated balloon (DCB) versus DCB with standard balloon predilation in moderate and severely calcified femoropopliteal arteries (Disrupt PAD III)
 Role: Principal Investigator
 Percent effort: 2%
 Direct costs per year: \$243,095.00
 Total costs for project period: \$279,559.25
 Project period: 12/1/2016 - 12/1/2021

Agency: Contego Medical
 I.D.#: 17-003533
 Title: Vanguard Study
 Role: Principal Investigator
 Percent effort: 5%
 Direct costs per year: \$49,200.00
 Total costs for project period: \$56,580.00
 Project period: 12/1/2016 - 11/30/2021

Agency: Intact Vascular

I.D.#: 17-003585
 Title: Tack Optimized Balloon Angioplasty Study for the Below the Knee Arteries
 Using the Tach Endovascular System (TOBA II- BTK)
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$337,800.00
 Total costs for project
 period: \$388,470.00
 Project period: 12/1/2016 - 11/30/2020

Agency: Intact Vascular
 I.D.#: 17-003585
 Title: TOBA II BTK
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$337,800.00
 Total costs for project
 period: \$388,470.00
 Project period: 12/1/2016 - 11/30/2021

Agency: Micell Technologies
 I.D.#: 17-003760
 Title: Crystal - China Sub Study
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$563,650.43
 Total costs for project
 period: \$648,198.00
 Project period: 12/1/2016 - 11/30/2021

Agency: Contego Medical
 I.D.#: 17-003533
 Title: Vanguard
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$49,200.00
 Total costs for project
 period: \$56,580.00
 Project period: 11/1/2016 - 10/31/2021

Agency: Shockwave Medical
 I.D.#: 17-003397
 Title: Disrupt PAD III
 Role: Principal Investigator

Percent effort: 1%
 Direct costs per year: \$358,190.00
 Total costs for project period: \$411,918.50
 Project period: 10/21/2016 - 10/20/2021

Agency: Caisson Interventional. LLC.
 I.D.#: 17-002722
 Title: Prelude First in Human
 Role: Principal Investigator
 Percent effort: 5%
 Direct costs per year: \$173,795.00
 Total costs for project period: \$199,864.25
 Project period: 10/1/2016 - 9/30/2021

Agency: Cagent Vascular. LLC.
 I.D.#: 17-002465
 Title: Multicenter, Prospective, Study for Femoropopliteal Arteries Using the Serranator Alto PTA Catheter
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$23,120.00
 Total costs for project period: \$26,588.00
 Project period: 10/1/2016 - 9/30/2021

Agency: TriReme
 I.D.#: 17-002762
 Title: Chocolate PTCA Balloom
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$60,787.50
 Total costs for project period: \$69,905.63
 Project period: 10/1/2016 - 9/30/2021

Agency: Shockwave Medical
 I.D.#: 17-002152
 Title: Shockwave Medical Lithoplasty BTK
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$15,640.00
 Total costs for project

period: \$17,986.00
Project period: 9/1/2016 - 8/30/2021

Agency: Sinomed
I.D.#: 17-001603
Title: Sinomed BuMA Supreme US IDE Clinical Trial
Role: Principal Investigator
Percent effort: 8%
Direct costs per year: \$881,987.00
Total costs for project period: \$1,014,285.12
Project period: 7/1/2016 - 6/30/2021

Agency: Lifetech Scientific (Shenzhen) Co., Ltd.
I.D.#: 16-005464
Title: Lifetech LAMBRE Device US IDE Clinical & Regulatory Trial Advisor
Role: Principal Investigator
Percent effort: 2%
Direct costs per year: \$1,019,520.00
Total costs for project period: \$1,172,448.00
Project period: 7/1/2016 - 6/30/2021

Agency: American College of Cardiology
I.D.#: 17-004353
Title: The National Registry of Left Atrial Appendage Closure Devices Evaluation
Role: Principal Investigator
Percent effort: 2%
Direct costs per year: \$61,774.00
Total costs for project period: \$71,040.00
Project period: 6/1/2016 - 2/1/2022

Agency: Bard Peripheral Vascular, Inc.
I.D.#: 17-001345
Title: A Prospective, Multi-Center, Single-Arm, Real-World Study Assessing the Clinical Use of the Bard UltraScore Focused Force PTA Balloon
Role: Principal Investigator
Percent effort: 2%
Direct costs per year: \$267,950.00
Total costs for project period: \$308,143.00
Project period: 6/1/2016 - 6/30/2021

Agency:	C.R. Bard, Inc.
I.D.#:	16-005175
Title:	A Prospective, Multicenter, Single Arm, Post-Approval Study of the Lutonix Drug Coated Balloon for the Treatment of Femoropopliteal Arteries in United States Females
Role:	Principal Investigator
Percent effort:	1%
Direct costs per year:	\$187,072.00
Total costs for project period:	\$215,133.00
Project period:	5/16/2016 - 5/15/2021
Agency:	Cardiatis S.A.
I.D.#:	16-005945
Title:	MFM Aortic Stent Graft US Early Feasibility Clinical Trial
Role:	Principal Investigator
Percent effort:	1%
Direct costs per year:	\$127,413.00
Total costs for project period:	\$146,525.00
Project period:	5/1/2016 - 5/1/2021
Agency:	TriReme Medical, Inc.
I.D.#:	16-004111
Title:	Endure Study
Role:	Principal Investigator
Percent effort:	1%
Direct costs per year:	\$27,050.00
Total costs for project period:	\$31,107.50
Project period:	1/6/2016 - 12/31/2020
Agency:	Bard Peripheral Vascular, Inc.
I.D.#:	16-003562
Title:	The BARD VENOVO Venous Stent Study – A Prospective, Non-Randomized, Multicenter, Single Arm Study of the Treatment of Iliofemoral Occlusive Disease an Assessment for Effectiveness and Safety (VERNACULAR)
Role:	Principal Investigator
Percent effort:	2%
Direct costs per year:	\$243,349.56
Total costs for project period:	\$279,852.50
Project period:	1/1/2016 - 12/31/2020

Agency: Cardiokinetix, Inc
 I.D.#: 13-002364
 Title: Parachute IV Echo Initiative
 Role: Principal Investigator
 Percent effort: 5%
 Direct costs per year: \$23,942.00
 Total costs for project period: \$27,533.00
 Project period: 12/1/2015 - 12/1/2020

Agency: C.R. Bard, Inc.
 I.D.#: 16-002221
 Title: A Prospective, Multicenter, Single Arm Trial Evaluating the BARD LTX DCB for Treatment of Femoropopliteal Arteries (Levant China)
 Role: Principal Investigator
 Percent effort: 2%
 Direct costs per year: \$96,970.43
 Total costs for project period: \$111,515.50
 Project period: 9/25/2015 - 9/24/2020

Agency: Bard Peripheral Vascular, Inc
 I.D.#: 16-002901
 Title: A Prospective, Multicenter, Randomized, Concurrently-Controlled Clinical Study of the Bard Covera Arteriovenous (AV) Stent Graft in the Treatment of Stenosis in the Venous Outflow of AV Fistula Access Circuits (AveNEW)
 Role: Principal Investigator
 Percent effort: 2%
 Direct costs per year: \$203,740.00
 Total costs for project period: \$234,301.00
 Project period: 9/1/2015 - 8/31/2020

Agency: W.L. Gore & Associates, Inc.
 I.D.#: 12-001431
 Title: Evaluation of the GORE CARDIOFORM ASD Occluder in the treatment of atrial septal defects
 Role: Principal Investigator
 Percent effort: 2%
 Direct costs per year: \$746,409.00
 Total costs for project period: \$858,370.00
 Project period: 8/1/2015 - 3/31/2021

Agency:	Shockwave Medical
I.D.#:	15-003435
Title:	Shockwave Lithoplasty DISRUPT Trial for PAD (DISRUPT PAD 2)
Role:	Principal Investigator
Percent effort:	1%
Direct costs per year:	\$80,450.00
Total costs for project period:	\$92,517.50
Project period:	6/9/2015 - 3/31/2020
Agency:	BioCardia, Inc.
I.D.#:	16-005042
Title:	Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Systems in Patients with Post Myocardial Infarction Heart Failure
Role:	Principal Investigator
Percent effort:	5%
Direct costs per year:	\$776,516.00
Total costs for project period:	\$881,493.00
Project period:	6/1/2015 - 5/31/2020
Agency:	W.L. Gore & Associates, Inc
I.D.#:	14-004810
Title:	Post-Approval Study of the GORE VIABHAN Endoprosthesis for Treatment of In-Stent Restenosis in the Superficial Femoral Artery
Role:	Principal Investigator
Percent effort:	2%
Direct costs per year:	\$86,695.00
Total costs for project period:	\$99,699.25
Project period:	5/18/2015 - 6/1/2020
Agency:	SurModics, Inc.
I.D.#:	15-005316
Title:	A Prospective, Multicenter, Single-Arm Trial to Assess the Safety and Feasibility of the SurModics Drug Coated Balloon in the Treatment of Subjects with De Novo Lesions of the Superficial Femoral Artery
Role:	Principal Investigator
Percent effort:	1%
Direct costs per year:	\$26,225.00
Total costs for project period:	\$30,158.75
Project period:	5/13/2015 - 5/4/2020

Agency: W.L. Gore & Associates, Inc.
 I.D.#: 18-005849
 Title: A Prospective, Global, Multicenter, Randomized, Controlled Study Comparing Lutonix 035 AV Drug Coated Balloon PTA Catheter vs. Standard Balloon PTA Catheter for the Treatment of Dysfunctional AV Fistulae (Lutonix AV)
 Role: Principal Investigator
 Percent effort: 2%
 Direct costs per year: \$208,500.00
 Total costs for project period: \$239,775.00
 Project period: 5/1/2015 - 4/30/2020

Agency: CorMatrix Cardiovascular
 I.D.#: 19-003541
 Title: CorMatrix ECM Tricuspid Valve Replacement Safety and Early Feasibility Study
 Role: Principal Investigator
 Percent effort: 2%
 Direct costs per year: \$94,025.00
 Total costs for project period: \$108,128.75
 Project period: 4/1/2015 - 3/31/2020

Agency: Shockwave Medical
 I.D.#: 15-004024
 Title: Shockwave Coronary Lithoplasty FIM
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$28,080.00
 Total costs for project period: \$32,292.00
 Project period: 3/1/2015 - 2/28/2020

Agency: Microvention, Inc.
 I.D.#: 15-003789
 Title: Carotid Stent Trial to Evaluate the Safety and Efficacy of the Roadsaver Stent Used in Conjunction with the Nanoparasol Embolic Protection System for Patients at Increased Risk for Adverse Events from Carotid Endarterectomy
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$112,655.00
 Total costs for project period: \$129,553.25
 Project period: 3/1/2015 - 2/28/2020

Agency:	Intact Vascular, LLC
I.D.#:	16-004288
Title:	TACK Optimized Drug Coated Balloon Angioplasty Study in the Superficial Femoral and Proximal Popliteal Arteries using the TACK Endovascular System (TOBA III)
Role:	Principal Investigator
Percent effort:	2%
Direct costs per year:	\$165,250.00
Total costs for project period:	\$190,038.00
Project period:	1/1/2015 - 12/1/2020
Agency:	Intact Vascular
I.D.#:	15-002982
Title:	TOBA Balloon Interim Analysis – Prospective multicenter Tack Optimized Balloon Angioplasty (TOBA) study for patients with femopopliteal stenosis using the Tack IT endovascular Stapler
Role:	Principal Investigator
Percent effort:	1%
Direct costs per year:	\$12,250.00
Total costs for project period:	\$14,087.00
Project period:	11/1/2014 - 11/1/2019
Agency:	TriReme Medical
I.D.#:	12-005608
Title:	Chocolate BAR Geographic Assessment- The Chocolate Balloon Angioplasty Registry,
Role:	Principal Investigator
Percent effort:	1%
Direct costs per year:	\$11,700.00
Total costs for project period:	\$13,455.00
Project period:	10/1/2014 - 10/1/2019
Agency:	CardioKinetics
I.D.#:	15-002202
Title:	Parachute China: PercutAneous Ventricular RestorAtion in Chronic Heart FailUre due to Ischemic HearT DiseasE CHINA
Role:	Principal Investigator
Percent effort:	5%
Direct costs per year:	\$81,470.00
Total costs for project	

period: \$93,690.00
Project period: 10/1/2014 - 10/1/2019

Agency: CardioKinetics
I.D.#: 14-002951
Title: Parachute Commercial: Percutaneous Ventricular Restoration in Chronic Heart Failure due to Ischemic Heart Disease Commercial
Role: Principal Investigator
Percent effort: 5%
Direct costs per year: \$27,300.00
Total costs for project period: \$31,395.00
Project period: 10/1/2014 - 10/1/2019

Agency: MicroPort
I.D.#: 15-003340
Title: TARGET US Pre IDE
Role: Principal Investigator
Percent effort: 1%
Direct costs per year: \$26,000.00
Total costs for project period: \$29,900.00
Project period: 10/1/2014 - 10/1/2019

Agency: Veryan Medical
I.D.#: 15-002827
Title: MIMICS 2: The Evaluation of Safety and Efficacy of the BioMimics 3DTM Stent
Role: Principal Investigator
Percent effort: 1%
Direct costs per year: \$277,400.00
Total costs for project period: \$319,010.00
Project period: 9/1/2014 - 9/1/2019

Agency: Intact Vascular
I.D.#: 14-004727
Title: TOBA BTK – Prospective multicenter Tack Optimized Balloon Angioplasty (TOBA) study for patients with femoropopliteal stenosis using the Tack IT endovascular Stapler- Below the knee
Role: Principal Investigator
Percent effort: 1%
Direct costs per year: \$37,890.00
Total costs for project period: \$43,573.00

Project period: 8/1/2014 - 8/1/2019

Current Clinical Trials

Agency: Keystone Heart, Inc.
 I.D.#: HIC# 1512016899
 Title: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation (REFLECT)
 P.I.: John Forrest
 Role: Sub-Investigator
 Percent effort: -
 Total costs for project period: -
 Project period: 3/4/2016

Agency: Gilead Sciences
 I.D.#: HIC# 1312013144
 Title: Ranolazine and Microvascular Angina by PET in the Emergency Department (RAMP-ED)
 P.I.: Basmah Safdar
 Role: Sub-Investigator
 Percent effort: -
 Total costs for project period: -
 Project period: 2/19/2014 - 10/12/2018

Agency: Medtronic, Inc
 I.D.#: HIC# 1211011066
 Title: Medtronic CoreValve Expanded Use Study
 P.I.: John Forrest
 Role: Sub-Investigator
 Percent effort: -
 Total costs for project period: -
 Project period: 12/6/2012

Past Grants

Agency: W.L Gore
 I.D.#: 19-004461
 Title: DCB 18 02 & DCB 18 03
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$997,600.00
 Total costs for project

period: \$1,147,240.00
Project period: 2/1/2019 - 6/3/2019

Agency: CardioKinetics
I.D.#: 15-001086
Title: Parachute Stent Fracture Analysis
Role: Principal Investigator
Percent effort: 5%
Direct costs per year: \$6,750.00
Total costs for project period: \$7,762.00
Project period: 6/1/2014 - 6/1/2019

Agency: C.R. Bard
I.D.#: 15-001088
Title: ACCESS- A Prospective, Multicenter, Single-arm, Post-market Study of
Role: Principal Investigator
Percent effort: 1%
Direct costs per year: \$16,200.00
Total costs for project period: \$18,630.00
Project period: 3/1/2014 - 3/1/2019

Agency: Gore
I.D.#: 14-004810
Title: Viabahn (BES 10-07) Evaluation of the GORE® VIABAHN® BALLOON EXPANDABLE ENDOPROSTHESIS (VIABAHN BX) for the Treatment of Occlusive Disease in the Common and External Iliac Arteries
Role: Principal Investigator
Percent effort: 1%
Direct costs per year: \$50,710.00
Total costs for project period: \$58,316.00
Project period: 2/1/2014 - 2/1/2019

Agency: Gore
I.D.#: 14-004810
Title: Viabahn (VBX 13-05) Evaluation of the GORE® VIABAHN® BALLOON EXPANDABLE ENDOPROSTHESIS (VIABAHN BX) for the Treatment of Occlusive Disease in the Common and External Iliac Arteries
Role: Principal Investigator
Percent effort: 1%
Direct costs per year: \$15,450.00
Total costs for project

period: \$17,767.00
Project period: 2/1/2014 - 2/1/2019

Agency: Micell
I.D.#: 14-004704
Title: Mistent Clinical Development Program
Role: Principal Investigator
Percent effort: 1%
Direct costs per year: \$220,450.00
Total costs for project period: \$25,357.00
Project period: 2/1/2014 - 2/1/2019

Agency: REVA Medical
I.D.#: 14-004397
Title: Fantom I and II: Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold
Role: Principal Investigator
Percent effort: 1%
Direct costs per year: \$205,780.00
Total costs for project period: \$236,647.00
Project period: 2/1/2014 - 2/1/2019

Agency: Shockwave Medical
I.D.#: 15-001899
Title: Lithoplasty System: Safety and Performance Study of the Shockwave Lithoplasty System
Role: Principal Investigator
Percent effort: 1%
Direct costs per year: \$36,020.00
Total costs for project period: \$41,423.00
Project period: 12/1/2013 - 12/1/2018

Agency: CorMatrix
I.D.#: 14-005414
Title: P-ECM
Role: Principal Investigator
Percent effort: 1%
Direct costs per year: \$39,844.71
Total costs for project period: \$45,821.42
Project period: 12/1/2013 - 12/1/2018

Agency: ReCor
 I.D.#: 14-003101
 Title: ACHIEVE: TrAnsCatHeter Intravascular ultrasound Energy deliVery for rEnal denervation
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$65,020.00
 Total costs for project period: \$74,773.00
 Project period: 11/1/2013 - 11/1/2018

Agency: Biotronik
 I.D.#: 13-002842
 Title: Biohelix SA– Multicenter randomized trial of the treatment of coronary artery lesions using the Pro-Kinetic Energy Cobalt Chromium Bare Metal stents-South America
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$0.00
 Total costs for project period: \$23,460.00
 Project period: 10/1/2013 - 10/1/2018

Agency: Boston Scientific
 I.D.#: 15-005153
 Title: REDUCE- HTN Trial: Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$48,380.00
 Total costs for project period: \$55,637.00
 Project period: 9/1/2013 - 9/1/2018

Agency: MicroPort
 I.D.#: 12-003214
 Title: FIREHAWK Post Market Trial- Multicenter European randomized trial evaluating a novel bioabsorbable DES in an all comers population of 2000 patients
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$299,580.00
 Total costs for project period: \$344,517.00
 Project period: 9/1/2012 - 9/1/2018

Agency: Phoenix Cardiac
 I.D.#: 14-001826
 Title: BACE: The Basal Annuloplasty of the Cardia Externally (BACE Device) Trial
 Role: Principal Investigator
 Percent effort: 5%
 Direct costs per year: \$147,800.00
 Total costs for project period: \$169,970.00
 Project period: 8/1/2013 - 8/1/2018

Agency: St. Jude Medical
 I.D.#: 14-001954
 Title: PORTICO EU
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$230,775.00
 Total costs for project period: \$265,391.25
 Project period: 8/1/2013 - 7/1/2018

Agency: Biotronik
 I.D.#: 14-003100
 Title: Bioflex South America
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$7,819.50
 Total costs for project period: \$8,992.43
 Project period: 6/1/2013 - 5/1/2018

Agency: Guided Delivery Systems
 I.D.#: 14-001124
 Title: GDS FIM South America
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$8,695.65
 Total costs for project period: \$10,000.00
 Project period: 5/1/2013 - 4/1/2018

Agency: W.L. Gore
 I.D.#: 18-001538
 Title: Gore Tigris TGR 14-18

Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$90,500.00
 Total costs for project period: \$104,075.00
 Project period: 9/1/2017 - 2/1/2018

Agency: Biotronik
 I.D.#: 13-002108
 Title: Biohelix I – Multicenter randomized trial of the treatment of coronary artery lesions using the Pro-Kinetic Energy Cobalt Chromium Bare Metal stents
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$120,564.00
 Total costs for project period: \$138,649.00
 Project period: 2/1/2013 - 1/1/2018

Agency: Abbott
 I.D.#: 17-005345
 Title: Absorb UK Registry
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$32,980.00
 Total costs for project period: \$37,927.00
 Project period: 12/1/2016 - 12/1/2017

Agency: Keystone Heart, Inc.
 I.D.#: 16-002973
 Title: The REFLECT US IDE Trial: A Randomized Evaluation of the TriGuard™ HD Embolic Deflection Device to Reduce the Volume of Cerebral Embolic Lesions and Improve Cognitive Outcomes After Transcatheter Aortic Valve Implantation
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$1,154,316.03
 Total costs for project period: \$1,327,463.44
 Project period: 9/1/2012 - 9/1/2017

Agency: Intact Vascular, LLC
 I.D.#: 13-001400
 Title: TOBA
 Role: Principal Investigator

Percent effort: 1%
 Direct costs per year: \$114,140.00
 Total costs for project period: \$131,261.00
 Project period: 8/2/2012 - 8/1/2017

Agency: Bard
 I.D.#: 14-001646
 Title: BOLSTER- A Prospective, Multi-Center, Non-Randomized Study of the BARD® Balloon-Expandable Covered Stent in the Treatment of Iliac Artery Occlusive Disease (BOLSTER)
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$221,230.00
 Total costs for project period: \$254,414.50
 Project period: 7/1/2012 - 7/1/2017

Agency: ReCor
 I.D.#: 12-003744
 Title: REALISE: Renal denervation by ultrasound transcatheter emission for refractory hypertension
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$24,200.00
 Total costs for project period: \$27,830.00
 Project period: 6/1/2012 - 6/1/2017

Agency: TriReme Medical
 I.D.#: 12-005608
 Title: Chocolate BAR
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$187,450.00
 Total costs for project period: \$215,567.50
 Project period: 6/1/2012 - 6/1/2017

Agency: TriReme Medical
 I.D.#: 13-001889
 Title: DCC FIH
 Role: Principal Investigator
 Percent effort: 1%

Direct costs per year: \$86,590.00
 Total costs for project period: \$99,578.50
 Project period: 5/1/2012 - 5/1/2017

Agency: W.L. Gore
 I.D.#: 12-001431
 Title: GORE Carotid Stent 10-08
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$212,500.00
 Total costs for project period: \$244,375.00
 Project period: 5/1/2011 - 5/1/2017

Agency: W.L. Gore
 I.D.#: 11-004156
 Title: TIGRIS – US IDE Registry
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$174,730.00
 Total costs for project period: \$200,939.50
 Project period: 5/1/2011 - 5/1/2017

Agency: Keystone Heart, Inc.
 I.D.#: 15-002821
 Title: Neuro TAVR- Multicenter international trial evaluating neuro-embolic ischemic burden and impact on neuro-cognitive function following TAVR
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$36,000.00
 Total costs for project period: \$41,400.00
 Project period: 4/1/2013 - 4/1/2017

Agency: Keystone Heart, Inc.
 I.D.#: 14-003616
 Title: DEFLECT III: A European Prospective, Randomized Evaluation of the TriGuard™ HDH Embolic DEFLECTION Device during Transcatheter Aortic Valve Implantation.
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$294,300.00

Total costs for project
period: \$338,445.00
Project period: 4/1/2013 - 4/1/2017

Agency: NeuroSave, Inc.
I.D.#: 16-003248
Title: US Clinical Regulatory
Role: Principal Investigator
Percent effort: 1%
Direct costs per year: \$25,175.00
Total costs for project
period: \$28,951.25
Project period: 12/15/2015 - 11/30/2016

Agency: Direct Flow Medical
I.D.#: 14-001080
Title: SALUS II Protocol Development
Role: Principal Investigator
Percent effort: 1%
Direct costs per year: \$25,400.00
Total costs for project
period: \$29,210.00
Project period: 2/1/2013 - 8/1/2016

Agency: CardioKinetix
I.D.#: 13-002364
Title: PARACHUTE IV
Role: Principal Investigator
Percent effort: 1%
Direct costs per year: \$465,243.70
Total costs for project
period: \$535,030.25
Project period: 6/1/2011 - 6/1/2016

Agency: CardioKinetix, Inc
I.D.#: 11-004285
Title: Parachute III
Role: Principal Investigator
Percent effort: 1%
Direct costs per year: \$303,500.00
Total costs for project
period: \$349,025.00
Project period: 6/1/2011 - 6/1/2016

Agency: Silkroad Medical
 I.D.#: 12-002001
 Title: ROADSTER
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$233,300.00
 Total costs for project period: \$256,795.00
 Project period: 11/1/2011 - 3/1/2016

Agency: Bridgepoint Medical
 I.D.#: 11-004352
 Title: Peripheral FAST CTO
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$26,250.00
 Total costs for project period: \$30,187.50
 Project period: 10/15/2010 - 10/14/2015

Agency: REVA Medical
 I.D.#: 13-002599
 Title: Restore II - Safety & Performance Study of the ReZolve2 Sirolimus-Eluting Bioresorbable Coronary Scaffold
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$189,655.00
 Total costs for project period: \$218,103.25
 Project period: 7/1/2012 - 6/1/2015

Agency: InspireMD
 I.D.#: 15-001463
 Title: CGuard Carenet-(CARotid Embolic protection using microNET)
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$10,800.00
 Total costs for project period: \$12,420.00
 Project period: 8/1/2014 - 12/1/2014

Agency: Bard
 I.D.#: 11-005359

Title: RESCUE – US IDE randomized clinical trial evaluating the FLUENCY Endovascular stent graft for in-stent restenosis of the AV access venous outflow circuit
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$155,940.00
 Total costs for project period: \$179,331.00
 Project period: 11/1/2010 - 11/1/2014

Agency: Keystone Heart, Inc.
 I.D.#: 12-001146
 Title: DEFLECT I Trial
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$235,710.76
 Total costs for project period: \$271,067.37
 Project period: 9/1/2011 - 9/1/2014

Agency: Direct Flow Medical
 I.D.#: 14-001307
 Title: U.S. Feasibility
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$19,950.00
 Total costs for project period: \$22,942.50
 Project period: 6/1/2013 - 5/1/2014

Agency: Kimberly Clark Health Care
 I.D.#: 13-004914
 Title: OxyGeneSys
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$11,425.00
 Total costs for project period: \$13,138.75
 Project period: 4/1/2013 - 3/1/2014

Agency: AVINGER, Inc.
 I.D.#: 13-004285
 Title: Combine South America
 Role: Principal Investigator
 Percent effort: 1%

Direct costs per year: \$11,338.33
 Total costs for project period: \$13,039.08
 Project period: 4/1/2013 - 3/1/2014

Agency: Micell Technologies
 I.D.#: 11-004842
 Title: Dessolve I
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$29,500.00
 Total costs for project period: \$33,925.00
 Project period: 11/1/2011 - 11/1/2012

Agency: Micell Technologies
 I.D.#: 11-004843
 Title: Dessolve II
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$123,410.43
 Total costs for project period: \$141,922.00
 Project period: 11/1/2010 - 11/1/2012

Agency: Entourage Medical Technologies, Inc.
 I.D.#: 12-004708
 Title: CardioClose Lit Search and Review
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$30,000.00
 Total costs for project period: \$34,500.00
 Project period: 4/1/2012 - 7/1/2012

Agency: HeartFlow, Inc.
 I.D.#: 11-004015
 Title: Discover-Flow
 Role: Principal Investigator
 Percent effort: 1%
 Direct costs per year: \$33,370.00
 Total costs for project period: \$38,375.50
 Project period: 2/1/2011 - 4/1/2011

Past Clinical Trials

Agency:	Yale University School of Medicine
I.D.#:	HIC# 1411014865
Title:	Computation of Fractional Flow Reserve by Quantitative Coronary Angiography: The FFRQCA Trial
Role:	Principal Investigator
Percent effort:	-
Total costs for project period:	-
Project period:	1/20/2015 - 5/31/2016
Agency:	Medtronic, Inc
I.D.#:	HIC# 1403013616
Title:	Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction (REFINE-ICD)
P.I.:	Rachel Lampert
Role:	Sub-Investigator
Percent effort:	-
Total costs for project period:	-
Project period:	4/16/2014 - 12/9/2015
Agency:	Keystone Heart, Inc.
I.D.#:	HIC# 1304011889
Title:	Neurological complications of contemporary unprotected TAVR (Yale NeuroTAVR)
Role:	Principal Investigator
Percent effort:	-
Total costs for project period:	-
Project period:	5/10/2013 - 11/12/2015
Agency:	Gilead Sciences
I.D.#:	HIC# 1202009644
Title:	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who Undergo Percutaneous Coronary Intervention with Incomplete Revascularization
Role:	Principal Investigator
Percent effort:	-
Total costs for project period:	-
Project period:	3/7/2012 - 11/3/2015

Agency: St. Jude Medical
 I.D.#: HIC# 1404013729
 Title: Portico Re-Sheathable Transcatheter Aortic Valve System US IDE Trial (Portico)
 P.I.: John Forrest
 Role: Sub-Investigator
 Percent effort: -
 Total costs for project period: -
 Project period: 5/21/2014 - 8/21/2015

Agency: Boston Scientific Corporation
 I.D.#: HIC# 1401013333
 Title: The Lumen Study: A Prospective, Multicenter, Open Label Randomized Study to Evaluate the Safety, Performance and Intraluminal Crossing of the TruePath CTO Device versus The Crosser System in Patients with Symptomatic Femoropopliteal Chronic Total Occlusion
 P.I.: Carlos Mena
 Role: Sub-Investigator
 Percent effort: -
 Total costs for project period: -
 Project period: 5/13/2014 - 6/19/2015

Agency: American College of Cardiology
 I.D.#: HIC# 1309012650
 Title: Championing High Quality Care for the Patient with Aortic Stenosis
 P.I.: John Forrest
 Role: Sub-Investigator
 Percent effort: -
 Total costs for project period: -
 Project period: 10/10/2013 - 11/6/2014

Agency: Medtronic, Inc
 I.D.#: HIC# 1310012783
 Title: Renal Denervation in Patients with Uncontrolled Hypertension - SYMPPLICITY HTN-4
 P.I.: Carlos Mena
 Role: Sub-Investigator
 Percent effort: -
 Total costs for project period: -
 Project period: 10/16/2013 - 4/21/2014

Pending Clinical Trials

Agency:	NO FUNDING
I.D.#:	HIC# 2000024617MRR
Title:	Multicenter Evaluation of Outcomes in Patients with Paradoxical Low-Flow, Low-gradient Versus Normalflow, High-gradient Symptomatic Severe Aortic Stenosis who underwent Transcatheter Aortic Valve Replacement: The PLO-FLOW TAVR study.
P.I.:	Ryan Kaple
Role:	Sub-Investigator
Percent effort:	-
Total costs for project period:	-
Project period:	1/14/2019
Agency:	MicroPort Medical (Shanghai) Co. Ltd.
I.D.#:	HIC# 1511016761
Title:	Target All Comer: A prospective multicenter post market trial to assess the safety and effectiveness of the Firehawk rapamycin target eluting cobalt chromium coronary stent system (Firehawk stent system) for the treatment of atherosclerotic lesion(s)
Role:	Principal Investigator
Percent effort:	-
Total costs for project period:	-
Project period:	11/18/2015
Agency:	Medtronic, Inc
I.D.#:	HIC# CABG
Title:	CABG Care Pathways Phase I a retrospective, single-arm, non-randomized, single center clinical study evaluating isolated CABG outcomes and costs of care and comparing to other centers regionally and nationally
Role:	Principal Investigator
Percent effort:	-
Total costs for project period:	-

Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated With Yale:

International/National

2018: San Diego, CA. "Ascending the Ladder: 5 Keys to a Successful Career in Interventional Cardiology"

2018: Suzhou, Jiangsu, China. "Road to excellence in Clinical Research – how to become a premier Research Center, Introduction and Objectives"

Bibliography:

Peer-Reviewed Original Research

1. Cottin Y, **Lansky AJ**, Kim HS, Kollum M, Abrahimi A, Mehran R, Bhargava B, Chan RC, Waksman R. Intracoronary brachytherapy not associated with changes in major side branches. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2000, 51:154-8.
2. Condado JA, Waksman R, Saucedo JF, Bhargava B, **Lansky AJ**, Calderas C, Gurdziel O, Gonzalez J, Fadoul M, Parra B, Iturria I, Amezaga B. Five-year clinical and angiographic follow-up after intracoronary iridium-192 radiation therapy. *Cardiovascular Radiation Medicine* 2002, 3:74-81.
3. Iakovou I, Dangas G, Mehran R, **Lansky AJ**, Stamou SC, Pfister AJ, Dullum MK, Leon MB, Corso PJ. Minimally invasive direct coronary artery bypass (MIDCAB) versus coronary artery stenting for elective revascularization of the left anterior descending artery. *The American Journal Of Cardiology* 2002, 90:885-7.
4. Morino Y, Kaneda H, Fox T, Takagi A, Hassan AH, Bonan R, Crocker I, **Lansky AJ**, Laskey WK, Suntharalingam M, Bonneau HN, Yock PG, Honda Y, Fitzgerald PJ. Delivered dose and vascular response after beta-radiation for in-stent restenosis: retrospective dosimetry and volumetric intravascular ultrasound analysis. *Circulation* 2002, 106:2334-9.
5. Waksman R, Buchbinder M, Reisman M, **Lansky AJ**, Trauthen B, Whiting J, Li A. Balloon-based radiation therapy for treatment of in-stent restenosis in human coronary arteries: results from the BRITE I study. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2002, 57:286-94.
6. Iakovou I, Dangas G, Mehran R, **Lansky AJ**, Kobayashi Y, Adamian M, Polena S, Collins MB, Roubin GS, Stone GW, Leon MB, Moses JW. Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors. *The American Journal Of Cardiology* 2002, 89:976-9.
7. Suntharalingam M, Laskey W, **Lansky AJ**, Waksman R, White L, Teirstien P, Massullo V, Rutherford B, Elman A, Kuntz RE, Popma JJ, Bonan R. Clinical and angiographic outcomes after use of 90Strontium/90Yttrium beta radiation for the treatment of in-stent restenosis: results from the Stents and Radiation Therapy 40 (START 40) registry. *International Journal Of Radiation Oncology, Biology, Physics* 2002, 52:1075-82.
8. Ashby DT, Dangas G, Mehran R, **Lansky AJ**, Narasimaiah R, Iakovou I, Polena S, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB. Comparison of clinical outcomes using stents versus no stents after percutaneous coronary intervention for proximal left anterior descending versus proximal right and left circumflex coronary arteries. *The American Journal Of Cardiology* 2002, 89:1162-6.
9. **Lansky AJ**, Mehran R, Dangas G, Desai K, Costantini-Ortiz C, Cristea E, New G, Negoita M, Stone GW, Leon MB. New-device angioplasty in women: clinical outcome and predictors in a 7,372-patient registry. *Epidemiology (Cambridge, Mass.)* 2002, 13 Suppl 3:S46-51.
10. Popma JJ, Suntharalingam M, **Lansky AJ**, Heuser RR, Speiser B, Teirstein PS, Massullo V, Bass T, Henderson R, Silber S, von Rottkay P, Bonan R, Ho KK, Osattin A, Kuntz RE. Randomized trial of

- 90Sr/90Y beta-radiation versus placebo control for treatment of in-stent restenosis. *Circulation* 2002, 106:1090-6.
11. Kuntz RE, Baim DS, Cohen DJ, Popma JJ, Carrozza JP, Sharma S, McCormick DJ, Schmidt DA, **Lansky AJ**, Ho KK, Dandreo KJ, Setum CM, Ramee SR. A trial comparing rheolytic thrombectomy with intracoronary urokinase for coronary and vein graft thrombus (the Vein Graft AngioJet Study [VeGAS 2]). *The American Journal Of Cardiology* 2002, 89:326-30.
12. Stone GW, Peterson MA, **Lansky AJ**, Dangas G, Mehran R, Leon MB. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. *Journal Of The American College Of Cardiology* 2002, 39:591-7.
13. Dangas G, Mehran R, Feldman D, Stoyioglou A, Pichard AD, Kent KM, Satler LF, Fahy M, **Lansky AJ**, Stone GW, Leon MB. Postprocedure creatine kinase-MB elevation and baseline left ventricular dysfunction predict one-year mortality after percutaneous coronary intervention. *The American Journal Of Cardiology* 2002, 89:586-9.
14. Waksman R, Raizner AE, Yeung AC, **Lansky AJ**, Vandertie L. Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. *Lancet* 2002, 359:551-7.
15. **Lansky AJ**, Desai K, Leon MB. Quantitative coronary angiography in regression trials: a review of methodologic considerations, endpoint selection, and limitations. *The American Journal Of Cardiology* 2002, 89:4B-9B.
16. Ajani AE, Waksman R, Zimarino M, Kim HS, Pichard AD, Satler LF, Kent KM, White RL, Pinnow E, Mehran R, **Lansky A**, Lindsay J. Device selection in the treatment of in-stent restenosis with and without radiation (from the Gamma Radiation Trials). *The American Journal Of Cardiology* 2002, 89:137-44.
17. Ashby DT, Dangas G, Mehran R, **Lansky AJ**, Fahy MP, Iakovou I, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB. Comparison of one-year outcomes after percutaneous coronary intervention among current smokers, ex-smokers, and nonsmokers. *The American Journal Of Cardiology* 2002, 89:221-4.
18. **Lansky AJ**, Dangas G, Mehran R, Desai KJ, Mintz GS, Wu H, Fahy M, Stone GW, Waksman R, Leon MB. Quantitative angiographic methods for appropriate end-point analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation. *Journal Of The American College Of Cardiology* 2002, 39:274-80.
19. Gercken U, **Lansky AJ**, Buellesfeld L, Desai K, Badereldin M, Mueller R, Selbach G, Leon MB, Grube E. Results of the Jostent coronary stent graft implantation in various clinical settings: procedural and follow-up results. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2002, 56:353-60.
20. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, **Lansky AJ**. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. *The New England Journal Of Medicine* 2002, 346:957-66.
21. Gruberg L, Dangas G, Mehran R, Mintz GS, Kent KM, Pichard AD, Satler LF, **Lansky AJ**, Stone GW, Leon MB. Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2002, 55:66-72.
22. Prpic R, Teirstein PS, Reilly JP, Moses JW, Tripuraneni P, **Lansky AJ**, Giorgianni JA, Jani S, Wong SC, Fish RD, Ellis S, Holmes DR, Kereiakas D, Kuntz RE, Leon MB. Long-term outcome of patients

- treated with repeat percutaneous coronary intervention after failure of gamma-brachytherapy for the treatment of in-stent restenosis. *Circulation* 2002, 106:2340-5.
23. Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A, Wiesinger B, Hak JB, Tieleman H, Ziemer G, Cristea E, **Lansky A**, Bérégi JP. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. *Circulation* 2002, 106:1505-9.
 24. Kataoka T, Grube E, Honda Y, Morino Y, Hur SH, Bonneau HN, Colombo A, Di Mario C, Guagliumi G, Hauptmann KE, Pitney MR, **Lansky AJ**, Stertzer SH, Yock PG, Fitzgerald PJ. 7-hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE). *Circulation* 2002, 106:1788-93.
 25. Morino Y, Limpijankit T, Honda Y, **Lansky AJ**, Waksman R, Bonneau HN, Yock PG, Mintz GS, Fitzgerald PJ. Late vascular response to repeat stenting for in-stent restenosis with and without radiation: an intravascular ultrasound volumetric analysis. *Circulation* 2002, 105:2465-8.
 26. Stone GW, Cox DA, Low R, Cates CU, Satler L, Bailey SR, Kuntz RE, **Lansky AJ**. Safety and efficacy of a novel device for treatment of thrombotic and atherosclerotic lesions in native coronary arteries and saphenous vein grafts: results from the multicenter X-Sizer for treatment of thrombus and atherosclerosis in coronary applications trial (X-TRACT) study. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2003, 58:419-27.
 27. Ashby DT, Mehran R, Aymong EA, **Lansky AJ**, Iakovou I, Weisz G, New G, Moussa I, Dangas G, Moses JW, Stone GW, Leon MB. Comparison of outcomes in men versus women having percutaneous coronary interventions in small coronary arteries. *The American Journal Of Cardiology* 2003, 91:979-81, A4, A7.
 28. Iakovou I, Dangas G, Mehran R, Mintz GS, **Lansky AJ**, Aymong ED, Nikolsky E, Vagaonescu T, Glasser LA, Stone GW, Leon MB, Moses JW. Comparison of effect of glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions on risk of hemorrhagic stroke in patients ≥ 75 years of age versus those < 75 years of age. *The American Journal Of Cardiology* 2003, 92:1083-6.
 29. Ashby DT, Aymong EA, Tcheng JE, Grines CL, Cox DA, Mehran R, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, **Lansky AJ**, Stone GW. Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial). *The American Journal Of Cardiology* 2003, 92:1091-4.
 30. Fujii K, Kobayashi Y, Mintz GS, Hirose M, Moussa I, Mehran R, Dangas G, **Lansky AJ**, Kreps E, Collins M, Colombo A, Stone GW, Leon MB, Moses JW. Dominant contribution of negative remodeling to development of significant coronary bifurcation narrowing. *The American Journal Of Cardiology* 2003, 92:59-61.
 31. Shirai K, **Lansky AJ**, Mintz GS, Costantini CO, Cristea E, Fahy M, Vandertie L, Yeung A, Raizner AE, Waksman R, Leon MB. Feasibility and efficacy of tandem positioning on angiographic and clinical outcomes in the Intimal Hyperplasia Inhibition with Beta In-Stent Trial. *The American Journal Of Cardiology* 2003, 91:1113-5.
 32. Costantini CO, **Lansky AJ**, Mintz GS, Shirai K, Teirstein PS, Stone G, Vandertie L, Proctor B, Fahy M, Yeung A, Raizner AE, Waksman R, Leon MB. Implications of the presence and length of "geographic miss" on restenosis and the edge phenomenon in the INHIBIT trial. *The American Journal Of Cardiology* 2003, 91:1261-5.
 33. Costantini CO, **Lansky AJ**, Mintz GS, Shirai K, Dangas G, Mehran R, Fahy M, Slack S, Coral M, Teirstein PS, Waksman R, Stone G, Moses J, Leon MB. Intravascular brachytherapy for native

- coronary ostial in-stent restenotic lesions. *Journal Of The American College Of Cardiology* 2003, 41:1725-31.
34. Iakovou I, Dangas G, Mehran R, **Lansky AJ**, Ashby DT, Fahy M, Mintz GS, Kent KM, Pichard AD, Satler LF, Stone GW, Leon MB. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. *The Journal Of Invasive Cardiology* 2003, 15:18-22.
 35. El-Omar MM, Dangas G, Mehran R, **Lansky AJ**, Kipshidze NN, Polena S, Fahy M, Moussa I, Glasser L, Moses JW, Stone GW, Leon MB. Usefulness of atrial fibrillation as a marker of outcome after percutaneous coronary intervention. *The American Journal Of Cardiology* 2003, 91:232-4.
 36. Kobayashi Y, Mehran R, Mintz GS, Dangas G, Moussa I, Collins M, Brara P, Moussavian M, **Lansky AJ**, Stone GW, Leon MB, Moses JW, Teirstein PS. Acute and long-term outcomes of cutting balloon angioplasty followed by gamma brachytherapy for in-stent restenosis. *The American Journal Of Cardiology* 2003, 92:1329-31.
 37. Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, **Lansky AJ**, Fahy M, Cox DA, Garcia E, Tchong JE, Griffin JJ, Stuckey TD, Turco M, Carroll JD. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. *Circulation* 2003, 108:2769-75.
 38. Iakovou I, Mintz GS, Dangas G, Abizaid A, Mehran R, Kobayashi Y, **Lansky AJ**, Aymong ED, Nikolsky E, Stone GW, Moses JW, Leon MB. Increased CK-MB release is a "trade-off" for optimal stent implantation: an intravascular ultrasound study. *Journal Of The American College Of Cardiology* 2003, 42:1900-5.
 39. Stone GW, Cox DA, Babb J, Nukta D, Bilodeau L, Cannon L, Stuckey TD, Hermiller J, Cohen EA, Low R, Bailey SR, **Lansky AJ**, Kuntz RE. Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries. *Journal Of The American College Of Cardiology* 2003, 42:2007-13.
 40. Shirai K, **Lansky AJ**, Mintz GS, Costantini CO, Fahy M, Mehran R, Dangas G, Moses JW, Stone GW, Waksman R, Leon MB. Comparison of the angiographic outcomes after beta versus gamma vascular brachytherapy for treatment of in-stent restenosis. *The American Journal Of Cardiology* 2003, 92:1409-13.
 41. Hirose M, Kobayashi Y, Mintz GS, Moussa I, Mehran R, **Lansky AJ**, Dangas G, Kreps EM, Collins MB, Stone GW, Colombo A, Leon MB, Moses JW. Correlation of coronary arterial remodeling determined by intravascular ultrasound with angiographic diameter reduction of 20% to 60%. *The American Journal Of Cardiology* 2003, 92:141-5.
 42. Stone GW, Mehran R, Midei M, Waksman R, Schaer GL, Negoita M, **Lansky AJ**, Buchbinder M. Usefulness of beta radiation for de novo and in-stent restenotic lesions in saphenous vein grafts. *The American Journal Of Cardiology* 2003, 92:312-4.
 43. Limpijankit T, Mehran R, Mintz GS, Dangas G, **Lansky AJ**, Kao J, Ashby DT, Moussa I, Stone GW, Moses JW, Leon MB, Teirstein PS. Long-term follow-up of patients after gamma intracoronary brachytherapy failure (from GAMMA-I, GAMMA-II, and SCRIPPS-III). *The American Journal Of Cardiology* 2003, 92:315-8.
 44. Ashby DT, Dangas G, Aymong EA, Farkouh ME, Mehran R, **Lansky AJ**, Moses JW, Leon MB, Stone GW. Relation between the degree of procedural anticoagulation and complications after coronary stent implantation. *The American Journal Of Cardiology* 2003, 92:319-22.
 45. Kobayashi Y, Mehran R, Mintz GS, Dangas G, Moussa I, **Lansky AJ**, Stone GW, Moses JW, Leon MB. Comparison of in-hospital and one-year outcomes after multiple coronary arterial stenting in

- patients > or =80 years old versus those <80 years old. The American Journal Of Cardiology 2003, 92:443-6.
46. Mehran R, Aymong ED, Ashby DT, Fischell T, Whitworth H, Siegel R, Thomas W, Wong SC, Narasimaiah R, **Lansky AJ**, Leon MB. Safety of an aspirin-alone regimen after intracoronary stenting with a heparin-coated stent: final results of the HOPE (HEPACOAT and an Antithrombotic Regimen of Aspirin Alone) study. Circulation 2003, 108:1078-83.
 47. Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, **Lansky AJ**, Mehran R, Stone GW. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2003, 108:1316-23.
 48. Suntharalingam M, Laskey WK, Tantibhedhyangkul W, **Lansky A**, Teirstein P, Bass T, Silber S, Rutherford B, Wilmer C, Popma JJ, Kuntz R, Bonan R. Vascular brachytherapy using a beta emitter source in diabetic patients with in-stent restenosis: angiographic and clinical outcomes. International Journal Of Radiation Oncology, Biology, Physics 2003, 57:536-42.
 49. Cox DA, Stone GW, Grines CL, Stuckey T, Cohen DJ, Tcheng JE, Garcia E, Guagliumi G, Iwaoka RS, Fahy M, Turco M, **Lansky AJ**, Griffin JJ, Mehran R. Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial. Journal Of The American College Of Cardiology 2003, 42:971-7.
 50. Ashby DT, Aymong EA, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Carroll JD, Turco M, **Lansky AJ**, Stone GW. Outcomes of bail-out stenting for suboptimal balloon angioplasty during primary intervention in acute myocardial infarction (The CADILLAC trial). The American Journal Of Cardiology 2003, 92:1095-8.
 51. Iakovou I, Mintz GS, Dangas G, Abizaid A, Mehran R, **Lansky AJ**, Kobayashi Y, Hirose M, Ashby DT, Stone GW, Moses JW, Leon MB. Optimal final lumen area and predictors of target lesion revascularization after stent implantation in small coronary arteries. The American Journal Of Cardiology 2003, 92:1171-6.
 52. Costantini CO, **Lansky AJ**, Mintz GS, Shirai K, Dangas G, Mehran R, Stone GW, Leon MB. Usefulness of the angiographic pattern of in-stent restenosis in predicting the success of gamma vascular brachytherapy. The American Journal Of Cardiology 2003, 92:1214-7.
 53. Fujii K, Kobayashi Y, Mintz GS, Takebayashi H, Dangas G, Moussa I, Mehran R, **Lansky AJ**, Kreps E, Collins M, Colombo A, Stone GW, Leon MB, Moses JW. Intravascular ultrasound assessment of ulcerated ruptured plaques: a comparison of culprit and nonculprit lesions of patients with acute coronary syndromes and lesions in patients without acute coronary syndromes. Circulation 2003, 108:2473-8.
 54. Rizik DG, Popma JP, Leon MB, Mintz GS, Weiner B, Cohen E, **Lansky AJ**, Adem AM, Bouhasin AP, Wojciechowski C, Weissman NJ. Benefits of cutting balloon before stenting. The Journal Of Invasive Cardiology 2003, 15:624-8.
 55. Heuser R, Laskey W, **Lansky A**, Popma J, Bonan R. Beta radiation in lesions > 15 mm: a START subgroup. The Journal Of Invasive Cardiology 2003, 15:641-3.
 56. Kereiakes DJ, Cox DA, Hermiller JB, Midei MG, Bachinsky WB, Nukta ED, Leon MB, Fink S, Marin L, **Lansky AJ**. Usefulness of a cobalt chromium coronary stent alloy. The American Journal Of Cardiology 2003, 92:463-6.
 57. Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A, Wiesinger B, Hak JB, Tielemans H, Ziemer G, Cristea E, **Lansky A**, Bérégí JP. Sirolimus-eluting stents for the treatment of obstructive

- superficial femoral artery disease: six-month results. *The Journal Of Invasive Cardiology* 2004, 16 Suppl A:15A-19A.
58. Nikolsky E, Mehran R, Turcot D, Aymong ED, Mintz GS, Lasic Z, **Lansky AJ**, Tsounias E, Moses JW, Stone GW, Leon MB, Dangas GD. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. *The American Journal Of Cardiology* 2004, 94:300-5.
 59. Petersen JL, Mahaffey KW, Becker RC, Goodman SG, Kleiman NS, Marian AJ, Stone GW, **Lansky AJ**, Lincoff AM, Hazen SL, Nessel CC, Toro-Figueroa L, Tate L, Reist CJ, Cohen M, Califf RM, Ferguson JJ. Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library. *American Heart Journal* 2004, 148:269-76.
 60. Sadeghi HM, Grines CL, Chandra HR, Mehran R, Fahy M, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Stuckey TD, **Lansky AJ**, O'Neill WW, Stone GW. Magnitude and impact of treatment delays on weeknights and weekends in patients undergoing primary angioplasty for acute myocardial infarction (the cadillac trial). *The American Journal Of Cardiology* 2004, 94:637-40, A9.
 61. Guagliumi G, Stone GW, Cox DA, Stuckey T, Tcheng JE, Turco M, Musumeci G, Griffin JJ, **Lansky AJ**, Mehran R, Grines CL, Garcia E. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. *Circulation* 2004, 110:1598-604.
 62. Nikolsky E, Aymong ED, Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Cohen DA, Negoita M, **Lansky AJ**, Stone GW. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. *Journal Of The American College Of Cardiology* 2004, 44:547-53.
 63. McLaughlin MG, Stone GW, Aymong E, Gardner G, Mehran R, **Lansky AJ**, Grines CL, Tcheng JE, Cox DA, Stuckey T, Garcia E, Guagliumi G, Turco M, Josephson ME, Zimetbaum P. Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. *Journal Of The American College Of Cardiology* 2004, 44:1215-23.
 64. Grube E, **Lansky A**, Hauptmann KE, Di Mario C, Di Sciascio G, Colombo A, Silber S, Stumpf J, Reifart N, Fajadet J, Marzocchi A, Schofer J, Dumas P, Hoffmann R, Guagliumi G, Pitney M, Russell ME. High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial. *Journal Of The American College Of Cardiology* 2004, 44:1368-72.
 65. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, **Lansky AJ**, Moses JW, Stone GW, Leon MB, Dangas G. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. *Journal Of The American College Of Cardiology* 2004, 44:1393-9.
 66. Takebayashi H, Mintz GS, Carlier SG, Kobayashi Y, Fujii K, Yasuda T, Costa RA, Moussa I, Dangas GD, Mehran R, **Lansky AJ**, Kreps E, Collins MB, Colombo A, Stone GW, Leon MB, Moses JW. Nonuniform strut distribution correlates with more neointimal hyperplasia after sirolimus-eluting stent implantation. *Circulation* 2004, 110:3430-4.

67. **Lansky AJ**, Mehran R, Dangas G, Cristea E, Shirai K, Costa R, Costantini C, Tsuchiya Y, Carlier S, Mintz G, Cottin Y, Stone G, Moses J, Leon MB. Comparison of differences in outcome after percutaneous coronary intervention in men versus women <40 years of age. *The American Journal Of Cardiology* 2004, 93:916-9.
68. **Lansky AJ**, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA, O'Shaughnessy C, Applegate RA, Cannon LA, Mooney M, Farah A, Tannenbaum MA, Yakubov S, Kereiakes DJ, Wong SC, Kaplan B, Cristea E, Stone GW, Leon MB, Knopf WD, O'Neill WW. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. *Circulation* 2004, 109:1948-54.
69. Shirai K, **Lansky AJ**, Mehran R, Dangas GD, Costantini CO, Fahy M, Slack S, Mintz GS, Stone GW, Leon MB. Minimally invasive coronary artery bypass grafting versus stenting for patients with proximal left anterior descending coronary artery disease. *The American Journal Of Cardiology* 2004, 93:959-62.
70. Iakovou I, Dangas G, Mintz GS, Mehran R, Kobayashi Y, D Aymong E, Hirose M, Ashby DT, **Lansky AJ**, Stone GW, Leon MB, Moses JW. Relation of final lumen dimensions in saphenous vein grafts after stent implantation to outcome. *The American Journal Of Cardiology* 2004, 93:963-8.
71. Mehran R, Dangas GD, Kobayashi Y, **Lansky AJ**, Mintz GS, Aymong ED, Fahy M, Moses JW, Stone GW, Leon MB. Short- and long-term results after multivessel stenting in diabetic patients. *Journal Of The American College Of Cardiology* 2004, 43:1348-54.
72. Pellizzon GG, Grines CL, Cox DA, Stuckey T, Tcheng JE, Garcia E, Guagliumi G, Turco M, **Lansky AJ**, Griffin JJ, Cohen DJ, Aymong E, Mehran R, O'Neill WW, Stone GW. Importance of mitral regurgitation in patients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. *Journal Of The American College Of Cardiology* 2004, 43:1368-74.
73. Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U, **Lansky AJ**, Fitzgerald PJ. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. *Circulation* 2004, 109:2168-71.
74. Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, Griffin JJ, Guagliumi G, Brodie B, Turco M, Rutherford BD, Aymong E, **Lansky AJ**, Stone GW. Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. *Journal Of The American College Of Cardiology* 2004, 43:1780-7.
75. Dangas G, Aymong ED, Mehran R, Tcheng JE, Grines CL, Cox DA, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, **Lansky AJ**, Stone GW. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). *The American Journal Of Cardiology* 2004, 94:983-8.
76. Nikolsky E, Mehran R, Aymong ED, Mintz GS, **Lansky AJ**, Lasic Z, Negoita M, Fahy M, Pocock SJ, Na Y, Krieger S, Moses JW, Stone GW, Leon MB, Dangas G. Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions. *The American Journal Of Cardiology* 2004, 94:1023-7.
77. Kandzari DE, Tcheng JE, Grines CL, Cox DA, Stuckey T, Griffin JJ, Turco M, Garcia E, Carroll JD, Fahy M, **Lansky AJ**, Mehran R, Stone GW. Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction. *The American Journal Of Cardiology* 2004, 94:1029-33.

78. Fujii K, Mintz GS, Kobayashi Y, Carlier SG, Takebayashi H, Jacoboff D, Yasuda T, Moussa I, Dangas G, Mehran R, **Lansky AJ**, Reyes A, Kreps E, Collins M, Stone GW, Leon MB, Moses JW. Vascular remodeling and plaque composition between focal and diffuse coronary lesions assessed by intravascular ultrasound. *The American Journal Of Cardiology* 2004, 94:1067-70.
79. Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, Feit F, **Lansky AJ**, Lincoff AM, Mehran R, Moses JW, Ohman M, White HD. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. *American Heart Journal* 2004, 148:764-75.
80. Costantini CO, Stone GW, Mehran R, Aymong E, Grines CL, Cox DA, Stuckey T, Turco M, Gersh BJ, Tchong JE, Garcia E, Griffin JJ, Guagliumi G, Leon MB, **Lansky AJ**. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. *Journal Of The American College Of Cardiology* 2004, 44:305-12.
81. Nikolsky E, Mehran R, Dangas GD, Lasic Z, Mintz GS, Negoita M, **Lansky AJ**, Stone GW, Moussa I, Iyer S, Na Y, Moses JW, Leon MB. Prognostic significance of cerebrovascular and peripheral arterial disease in patients having percutaneous coronary interventions. *The American Journal Of Cardiology* 2004, 93:1536-9.
82. Iakovou I, Mehran R, Dangas G, **Lansky AJ**, Stone GW, Mintz GS, Aymong E, Ashby DT, Pichard AD, Satler LF, Kent K, Leon MB, Waksman R. Favorable effect of gamma-radiation for in-stent restenosis: effect of diabetes on angiographic and clinical outcomes. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2004, 62:303-7.
83. Nikolsky E, Mehran R, Mintz GS, Dangas GD, **Lansky AJ**, Aymong ED, Negoita M, Fahy M, Moussa I, Roubin GS, Moses JW, Stone GW, Leon MB. Impact of symptomatic peripheral arterial disease on 1-year mortality in patients undergoing percutaneous coronary interventions. *Journal Of Endovascular Therapy : An Official Journal Of The International Society Of Endovascular Specialists* 2004, 11:60-70.
84. Iakovou I, Dangas G, Mintz GS, Mehran R, **Lansky AJ**, Aymong ED, Nikolsky E, Vagaonescu T, Glasser LA, Stone GW, Leon MB, Moses JW. Comparison of frequency of hemorrhagic stroke in patients <75 years versus > or =75 years of age among patients receiving glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions. *The American Journal Of Cardiology* 2004, 93:346-9.
85. Halkin A, Aymong E, Cox DA, Mehran R, **Lansky AJ**, Fahy M, Weisz G, Garcia E, Tchong JE, Grines CL, Stone GW. Relation between late patency of the infarct-related artery, left ventricular function, and clinical outcomes after primary percutaneous intervention for acute myocardial infarction (CADILLAC trial). *The American Journal Of Cardiology* 2004, 93:349-53.
86. **Lansky AJ**. Outcomes of percutaneous and surgical revascularization in women. *Progress In Cardiovascular Diseases* 2004, 46:305-19.
87. Mehran R, Iakovou I, Dangas G, **Lansky AJ**, Stone GW, Mintz GS, Kent KM, Pichard AD, Satler LF, Fahy M, Leon MB, Waksman R. Gamma radiation for in-stent restenosis: effect of lesion length on angiographic and clinical outcomes. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2004, 61:354-9.
88. Fujii K, Mintz GS, Kobayashi Y, Carlier SG, Takebayashi H, Yasuda T, Moussa I, Dangas G, Mehran R, **Lansky AJ**, Reyes A, Kreps E, Collins M, Colombo A, Stone GW, Teirstein PS, Leon MB, Moses JW. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. *Circulation* 2004, 109:1085-8.

89. Sharma SK, Kini A, Mehran R, **Lansky A**, Kobayashi Y, Marmur JD. Randomized trial of Rotational Atherectomy Versus Balloon Angioplasty for Diffuse In-stent Restenosis (ROSTER). *American Heart Journal* 2004, 147:16-22.
90. **Lansky AJ**, Hochman JS, Ward PA, Mintz GS, Fabunmi R, Berger PB, New G, Grines CL, Pietras CG, Kern MJ, Ferrell M, Leon MB, Mehran R, White C, Mieres JH, Moses JW, Stone GW, Jacobs AK. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association. *Circulation* 2005, 111:940-53.
91. Costa RA, Mintz GS, Carlier SG, **Lansky AJ**, Moussa I, Fujii K, Takebayashi H, Yasuda T, Costa JR, Tsuchiya Y, Jensen LO, Cristea E, Mehran R, Dangas GD, Iyer S, Collins M, Kreps EM, Colombo A, Stone GW, Leon MB, Moses JW. Bifurcation coronary lesions treated with the "crush" technique: an intravascular ultrasound analysis. *Journal Of The American College Of Cardiology* 2005, 46:599-605.
92. Fujii K, Carlier SG, Mintz GS, Yang YM, Moussa I, Weisz G, Dangas G, Mehran R, **Lansky AJ**, Kreps EM, Collins M, Stone GW, Moses JW, Leon MB. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. *Journal Of The American College Of Cardiology* 2005, 45:995-8.
93. **Lansky AJ**, Pietras C, Costa RA, Tsuchiya Y, Brodie BR, Cox DA, Aymong ED, Stuckey TD, Garcia E, Tchong JE, Mehran R, Negoita M, Fahy M, Cristea E, Turco M, Leon MB, Grines CL, Stone GW. Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. *Circulation* 2005, 111:1611-8.
94. **Lansky AJ**, Costa RA, Mooney M, Midei MG, Lui HK, Strickland W, Mehran R, Leon MB, Russell ME, Ellis SG, Stone GW. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. *Journal Of The American College Of Cardiology* 2005, 45:1180-5.
95. Kim YH, Lee CW, Hong MK, Park SW, Tahk SJ, Yang JY, Saito S, Santoso T, Quan L, Ge J, Weissman NJ, **Lansky AJ**, Mintz GS, Park SJ. Randomized comparison of carbon ion-implanted stent versus bare metal stent in coronary artery disease: the Asian Pacific Multicenter Arthos Stent Study (PASS) trial. *American Heart Journal* 2005, 149:336-41.
96. Halkin A, Singh M, Nikolsky E, Grines CL, Tchong JE, Garcia E, Cox DA, Turco M, Stuckey TD, Na Y, **Lansky AJ**, Gersh BJ, O'Neill WW, Mehran R, Stone GW. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. *Journal Of The American College Of Cardiology* 2005, 45:1397-405.
97. Halkin A, Stone GW, Dixon SR, Grines CL, Tchong JE, Cox DA, Garcia E, Brodie B, Stuckey TD, Mehran R, **Lansky AJ**. Impact and determinants of left ventricular function in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction. *The American Journal Of Cardiology* 2005, 96:325-31.
98. Fujii K, Carlier SG, Mintz GS, Takebayashi H, Yasuda T, Costa RA, Moussa I, Dangas G, Mehran R, **Lansky AJ**, Kreps EM, Collins M, Stone GW, Moses JW, Leon MB. Intravascular ultrasound study of patterns of calcium in ruptured coronary plaques. *The American Journal Of Cardiology* 2005, 96:352-7.
99. Weisz G, Cox DA, Garcia E, Tchong JE, Griffin JJ, Guagliumi G, Stuckey TD, Rutherford BD, Mehran R, Aymong E, **Lansky A**, Grines CL, Stone GW. Impact of smoking status on outcomes of primary

- coronary intervention for acute myocardial infarction--the smoker's paradox revisited. *American Heart Journal* 2005, 150:358-64.
100. Nikolsky E, Sadeghi HM, Effron MB, Mehran R, **Lansky AJ**, Na Y, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Stuckey TD, Turco M, Carroll JD, Grines CL, Stone GW. Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. *The American Journal Of Cardiology* 2005, 96:474-81.
 101. Schlüter M, Tübler T, **Lansky AJ**, Kähler S, Berger J, Mathey DG, Schofer J. Angiographic and clinical outcomes at 8 months of cutting balloon angioplasty and beta-brachytherapy for native vessel in-stent restenosis (BETACUT): results from a stopped randomized controlled trial. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2005, 66:320-6.
 102. Sorajja P, Gersh BJ, Costantini C, McLaughlin MG, Zimetbaum P, Cox DA, Garcia E, Tcheng JE, Mehran R, **Lansky AJ**, Kandzari DE, Grines CL, Stone GW. Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. *European Heart Journal* 2005, 26:667-74.
 103. Stone GW, Webb J, Cox DA, Brodie BR, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Dulas D, Rutherford BD, Antoniucci D, Krucoff MW, Gibbons RJ, Jones D, **Lansky AJ**, Mehran R. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. *JAMA* 2005, 293:1063-72.
 104. Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Tielbeek A, Anderson J, Wiesinger B, Tepe G, **Lansky A**, Mudde C, Tielemans H, Béréggi JP. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. *Journal Of Vascular And Interventional Radiology : JVIR* 2005, 16:331-8.
 105. Stuckey TD, Stone GW, Cox DA, Tcheng JE, Garcia E, Carroll J, Guagliumi G, Rutherford BD, Griffin JJ, Turco M, **Lansky AJ**, Mehran R, Fahy M, Brodie BR, Grines CL. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). *The American Journal Of Cardiology* 2005, 95:1-7.
 106. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, **Lansky AJ**, Moussa I, Stone GW, Moses JW, Leon MB, Mehran R. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. *The American Journal Of Cardiology* 2005, 95:13-9.
 107. Costa RA, **Lansky AJ**, Mintz GS, Mehran R, Tsuchiya Y, Negoita M, Gilutz Y, Nikolsky E, Fahy M, Pop R, Cristea E, Carlier S, Dangas G, Stone GW, Leon MB, Müller R, Techen G, Grube E. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). *The American Journal Of Cardiology* 2005, 95:113-6.
 108. Fujii K, Carlier SG, Mintz GS, Kobayashi Y, Jacoboff D, Nierenberg H, Takebayashi H, Yasuda T, Moussa I, Dangas G, Mehran R, **Lansky AJ**, Kreps EM, Collins M, Stone GW, Leon MB, Moses JW. Creatine kinase-MB enzyme elevation and long-term clinical events after successful coronary stenting in lesions with ruptured plaque. *The American Journal Of Cardiology* 2005, 95:355-9.
 109. Nikolsky E, Mehran R, Lasic Z, Mintz GS, **Lansky AJ**, Na Y, Pocock S, Negoita M, Moussa I, Stone GW, Moses JW, Leon MB, Dangas G. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. *Kidney International* 2005, 67:706-13.
 110. Takebayashi H, Kobayashi Y, Mintz GS, Carlier SG, Fujii K, Yasuda T, Moussa I, Mehran R, Dangas GD, Collins MB, Kreps E, **Lansky AJ**, Stone GW, Leon MB, Moses JW. Intravascular ultrasound

- assessment of lesions with target vessel failure after sirolimus-eluting stent implantation. The American Journal Of Cardiology 2005, 95:498-502.
111. Prasad A, Stone GW, Stuckey TD, Costantini CO, Zimetbaum PJ, McLaughlin M, Mehran R, Garcia E, Tchong JE, Cox DA, Grines CL, **Lansky AJ**, Gersh BJ. Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. Journal Of The American College Of Cardiology 2005, 45:508-14.
112. de Ribamar Costa J, Mintz GS, Carlier SG, Costa RA, Fujii K, Sano K, Kimura M, Lui J, Weisz G, Moussa I, Dangas G, Mehran R, **Lansky AJ**, Kreps EM, Collins M, Stone GW, Moses JW, Leon MB. Intravascular ultrasonic assessment of stent diameters derived from manufacturer's compliance charts. The American Journal Of Cardiology 2005, 96:74-8.
113. Silber S, Popma JJ, Suntharalingam M, **Lansky AJ**, Heuser RR, Speiser B, Teirstein PS, Bass T, O'Neill W, Lasala J, Reisman M, Sharma SK, Kuntz RE, Bonan R. Two-year clinical follow-up of 90Sr/90 Y beta-radiation versus placebo control for the treatment of in-stent restenosis. American Heart Journal 2005, 149:689-94.
114. Sano K, Mintz GS, Carlier SG, Fujii K, Takebayashi H, Kimura M, Costa JR, Tanaka K, Costa RA, Lui J, Weisz G, Moussa I, Dangas GD, Mehran R, **Lansky AJ**, Kreps EM, Collins M, Stone GW, Moses JW, Leon MB. Volumetric intravascular ultrasound assessment of neointimal hyperplasia and nonuniform stent strut distribution in sirolimus-eluting stent restenosis. The American Journal Of Cardiology 2006, 98:1559-62.
115. Kimura M, Mintz GS, Carlier S, Takebayashi H, Fujii K, Sano K, Yasuda T, Costa RA, Costa JR, Quen J, Tanaka K, Lui J, Weisz G, Moussa I, Dangas G, Mehran R, **Lansky AJ**, Kreps EM, Collins M, Stone GW, Moses JW, Leon MB. Outcome after acute incomplete sirolimus-eluting stent apposition as assessed by serial intravascular ultrasound. The American Journal Of Cardiology 2006, 98:436-42.
116. Sano K, Mintz GS, Carlier SG, Fujii K, Yasuda T, Kimura M, Costa JR, Costa RA, Lui J, Weisz G, Moussa I, Dangas GD, Mehran R, **Lansky AJ**, Kreps EM, Collins M, Stone GW, Moses JW, Leon MB. Intravascular ultrasonic differences between aorto-ostial and shaft narrowing in saphenous veins used as aortocoronary bypass grafts. The American Journal Of Cardiology 2006, 97:1463-6.
117. Kaneda H, Honda Y, Morino Y, **Lansky AJ**, Yock PG, Bonan R, Fitzgerald PJ. Predictors of recurrent in-stent restenosis after beta-radiation: An analysis from the START 40/20 trial. Journal Of Interventional Cardiology 2006, 19:376-80.
118. Nikolsky E, Stone GW, Grines CL, Cox DA, Garcia E, Tchong JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Negoita M, **Lansky AJ**, Mehran R. Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction. American Heart Journal 2006, 151:168-75.
119. Price MJ, Cristea E, Sawhney N, Kao JA, Moses JW, Leon MB, Costa RA, **Lansky AJ**, Teirstein PS. Serial angiographic follow-up of sirolimus-eluting stents for unprotected left main coronary artery revascularization. Journal Of The American College Of Cardiology 2006, 47:871-7.
120. Halkin A, Stone GW, Grines CL, Cox DA, Rutherford BD, Esente P, Meils CM, Albertsson P, Farah A, Tchong JE, **Lansky AJ**, Mehran R. Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction. Journal Of The American College Of Cardiology 2006, 47:951-61.
121. Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Oliva V, Tielbeek A, Anderson J, Wiesinger B, Tepe G, **Lansky A**, Jaff MR, Mudde C, Tielemans H, Beregi JP. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from

- the SIROCCO trial. *Journal Of Endovascular Therapy : An Official Journal Of The International Society Of Endovascular Specialists* 2006, 13:701-10.
122. Brodie BR, Stone GW, Cox DA, Stuckey TD, Turco M, Tcheng JE, Berger P, Mehran R, McLaughlin M, Costantini C, **Lansky AJ**, Grines CL. Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial. *American Heart Journal* 2006, 151:1231-8.
 123. Kandzari DE, Tcheng JE, Gersh BJ, Cox DA, Stuckey T, Turco M, Mehran R, Garcia E, Zimetbaum P, McLaughlin MG, **Lansky AJ**, Costantini CO, Grines CL, Stone GW. Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction. *American Heart Journal* 2006, 151:1288-95.
 124. Cox DA, Stone GW, Grines CL, Stuckey T, Zimetbaum PJ, Tcheng JE, Turco M, Garcia E, Guagliumi G, Iwaoka RS, Mehran R, O'Neill WW, **Lansky AJ**, Griffin JJ. Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial). *The American Journal Of Cardiology* 2006, 98:331-7.
 125. **Lansky AJ**, Yang YM, Khan Y, Costa RA, Pietras C, Tsuchiya Y, Cristea E, Collins M, Mehran R, Dangas GD, Moses JW, Leon MB, Stone GW. Treatment of coronary artery perforations complicating percutaneous coronary intervention with a polytetrafluoroethylene-covered stent graft. *The American Journal Of Cardiology* 2006, 98:370-4.
 126. Costa RA, **Lansky AJ**, Abizaid A, Müller R, Tsuchiya Y, Mori K, Cristea E, Leon MB, Sousa JE, Schmidt T, Hauptmann KE, Grube E. Angiographic results of the first human experience with the Biolimus A9 drug-eluting stent for de novo coronary lesions. *The American Journal Of Cardiology* 2006, 98:443-6.
 127. Tsuchiya Y, **Lansky AJ**, Costa RA, Mehran R, Pietras C, Shimada Y, Sonoda S, Cristea E, Negoita M, Dangas GD, Moses JW, Leon MB, Fitzgerald PJ, Müller R, Störger H, Hauptmann KE, Grube E. Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). *The American Journal Of Cardiology* 2006, 98:464-9.
 128. Moussa I, Costa RA, Leon MB, **Lansky AJ**, Lasic Z, Cristea E, Trubelja N, Carlier SG, Mehran R, Dangas GD, Weisz G, Kreps EM, Collins M, Stone GW, Moses JW. A prospective registry to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions using the "crush technique". *The American Journal Of Cardiology* 2006, 97:1317-21.
 129. Chacko M, Lincoff AM, Wolski KE, Cohen DJ, Bittl JA, **Lansky AJ**, Tsuchiya Y, Betriu A, Yen MH, Chew DP, Cho L, Topol EJ. Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. *American Heart Journal* 2006, 151:1032.e1-7.
 130. Costa RA, **Lansky AJ**. [Sirolimus-eluting stents for the treatment of stenoses in small coronary arteries: what have we learned?]. *Arquivos Brasileiros De Cardiologia* 2006, 86:245-8.
 131. Price MJ, Moses JW, Leon MB, Mehran R, Negoita M, **Lansky A**, Collins M, Giap H, Lin R, Jani S, Steuterman S, Balter S, Dalton J, Lipsztein R, Tripuraneni P, Teirstein PS. A multicenter, randomized, dose-finding study of gamma intracoronary radiation therapy to inhibit recurrent restenosis after stenting. *The Journal Of Invasive Cardiology* 2006, 18:169-73.
 132. Moses JW, Stone GW, Nikolsky E, Mintz GS, Dangas G, Grube E, Ellis SG, **Lansky AJ**, Weisz G, Fahy M, Na Y, Russell ME, Donohoe D, Leon MB, Mehran R. Drug-eluting stents in the treatment of

- intermediate lesions: pooled analysis from four randomized trials. *Journal Of The American College Of Cardiology* 2006, 47:2164-71.
133. Costa RA, Sousa JE, Abizaid A, Chaves A, Feres F, Sousa AG, Musumeci G, Mehran R, Fitzgerald PJ, **Lansky AJ**, Leon MB, Shiran A, Halon DA, Lewis BS, Guagliumi G. The randomised study of the double dose versus single dose sirolimus-eluting stent for the treatment of diabetic patients with de novo coronary lesions. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2006, 2:295-301.
 134. Kaneda H, Honda Y, Morino Y, Fox T, Crocker I, **Lansky AJ**, Yock PG, Bonan R, Fitzgerald PJ. Safety of beta radiation exposure to the non-target segment: an intravascular ultrasound dosimetric analysis. *The Journal Of Invasive Cardiology* 2006, 18:309-12.
 135. Sano K, Mintz GS, Carlier SG, Solinas E, Costa Jde R, Qian J, Missel E, Shan S, Franklin-Bond T, Boland P, Weisz G, Moussa I, Dangas G, Mehran R, **Lansky AJ**, Kreps E, Collins M, Stone GW, Moses JW, Leon MB. Treatment of restenotic drug-eluting stents: an intravascular ultrasound analysis. *The Journal Of Invasive Cardiology* 2007, 19:464-8.
 136. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, **Lansky A**, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. *Circulation* 2007, 115:2344-51.
 137. Nikolsky E, Pucelikova T, Mehran R, Balter S, Kaufman L, Fahy M, **Lansky AJ**, Leon MB, Moses JW, Stone GW, Dangas G. An evaluation of fluoroscopy time and correlation with outcomes after percutaneous coronary intervention. *The Journal Of Invasive Cardiology* 2007, 19:208-13.
 138. Abizaid A, **Lansky AJ**, Fitzgerald PJ, Tanajura LF, Feres F, Staico R, Mattos L, Abizaid A, Chaves A, Centemero M, Sousa AG, Sousa JE, Zaugg MJ, Schwartz LB. Percutaneous coronary revascularization using a trilayer metal phosphorylcholine-coated zotarolimus-eluting stent. *The American Journal Of Cardiology* 2007, 99:1403-8.
 139. Marso SP, Miller T, Rutherford BD, Gibbons RJ, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Mehran R, Krucoff MW, **Lansky AJ**, Stone GW. Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial). *The American Journal Of Cardiology* 2007, 100:206-10.
 140. Sorajja P, Gersh BJ, Mehran R, **Lansky AJ**, Krucoff MW, Webb J, Cox DA, Brodie BR, Stone GW. Impact of collateral flow on myocardial reperfusion and infarct size in patients undergoing primary angioplasty for acute myocardial infarction. *American Heart Journal* 2007, 154:379-84.
 141. Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, Stuckey T, Tchong JE, Mehran R, **Lansky AJ**, Grines CL, Stone GW. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. *European Heart Journal* 2007, 28:1709-16.
 142. Brodie BR, Webb J, Cox DA, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Dulas D, Rutherford B, Antonucci D, Stuckey T, Krucoff M, Gibbons R, **Lansky A**, Na Y, Mehran R, Stone GW. Impact of time to treatment on myocardial reperfusion and infarct size with primary percutaneous coronary intervention for acute myocardial infarction (from the EMERALD Trial). *The American Journal Of Cardiology* 2007, 99:1680-6.
 143. Grube E, Buellesfeld L, Neumann FJ, Verheye S, Abizaid A, McClean D, Mueller R, **Lansky A**, Mehran R, Costa R, Gerckens U, Trauthen B, Fitzgerald PJ. Six-month clinical and angiographic results of a

- dedicated drug-eluting stent for the treatment of coronary bifurcation narrowings. *The American Journal Of Cardiology* 2007, 99:1691-7.
144. Echols MR, Mahaffey KW, Banerjee A, Pieper KS, Stebbins A, **Lansky A**, Cohen MG, Velazquez E, Santos R, Newby LK, Gurfinkel EP, Biasucci L, Ferguson JJ, Califf RM. Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial). *The American Journal Of Cardiology* 2007, 99:315-21.
 145. Young JJ, Cox DA, Stuckey T, Babb J, Turco M, **Lansky AJ**, Mehran R, Stone GW. Prospective, multicenter study of thrombectomy in patients with acute myocardial infarction: the X-Tract AMI registry. *Journal Of Interventional Cardiology* 2007, 20:44-50.
 146. Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, **Lansky AJ**, Mehran R, Moses JW. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. *Lancet* 2007, 369:907-19.
 147. Nikolsky E, Grines CL, Cox DA, Garcia E, Tcheng JE, Sadeghi M, Mehran R, **Lansky AJ**, Na Y, Stone GW. Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial). *The American Journal Of Cardiology* 2007, 99:1055-61.
 148. Prasad A, Stone GW, Stuckey TD, Costantini CO, Mehran R, Garcia E, Tcheng JE, Cox DA, Grines CL, **Lansky AJ**, Gersh BJ. Relation between leucocyte count, myonecrosis, myocardial perfusion, and outcomes following primary angioplasty. *The American Journal Of Cardiology* 2007, 99:1067-71.
 149. Harjai KJ, Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Na Y, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Rutherford BD, **Lansky AJ**, Mehran R. Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoprotein IIb/IIIa inhibitors. *The American Journal Of Cardiology* 2007, 99:202-7.
 150. de Ribamar Costa J, Mintz GS, Carlier SG, Mehran R, Teirstein P, Sano K, Liu X, Lui J, Na Y, Castellanos C, Biro S, Dani L, Rinker J, Moussa I, Dangas G, **Lansky AJ**, Kreps EM, Collins M, Stone GW, Moses JW, Leon MB. Nonrandomized comparison of coronary stenting under intravascular ultrasound guidance of direct stenting without predilation versus conventional predilation with a semi-compliant balloon versus predilation with a new scoring balloon. *The American Journal Of Cardiology* 2007, 100:812-7.
 151. Abizaid A, Chaves AJ, Leon MB, Hauptmann K, Mehran R, **Lansky AJ**, Baumbach W, Shankar H, Muller R, Feres F, Sousa AG, Sousa JE, Grube E. Randomized, double-blind, multicenter study of the polymer-based 17-beta estradiol-eluting stent for treatment of native coronary artery lesions: six-month results of the ETHOS I trial. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2007, 70:654-60.
 152. Sano K, Mintz GS, Carlier SG, de Ribamar Costa J, Qian J, Missel E, Shan S, Franklin-Bond T, Boland P, Weisz G, Moussa I, Dangas GD, Mehran R, **Lansky AJ**, Kreps EM, Collins MB, Stone GW, Leon MB, Moses JW. Assessing intermediate left main coronary lesions using intravascular ultrasound. *American Heart Journal* 2007, 154:983-8.
 153. Solinas E, Nikolsky E, **Lansky AJ**, Kirtane AJ, Morice MC, Popma JJ, Schofer J, Schampaert E, Pucelikova T, Aoki J, Fahy M, Dangas GD, Moses JW, Cutlip DE, Leon MB, Mehran R. Gender-

- specific outcomes after sirolimus-eluting stent implantation. *Journal Of The American College Of Cardiology* 2007, 50:2111-6.
154. Kaul U, Gupta RK, Mathur A, Dani S, Sapra R, Nayak PR, **Lansky A**, Cristea E, Carlier S, Gambone L, Litvack F. Cobalt chromium stent with antiproliferative for restenosis trial in India (COSTAR I). *Indian Heart Journal* 2007, 59:165-72.
 155. Pocock SJ, **Lansky AJ**, Mehran R, Popma JJ, Fahy MP, Na Y, Dangas G, Moses JW, Pucelikova T, Kandzari DE, Ellis SG, Leon MB, Stone GW. Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. *Journal Of The American College Of Cardiology* 2008, 51:23-32.
 156. Park SW, Lee SW, Koo BK, Park DW, Lee SW, Kim YH, Lee CW, Hong MK, Kim JJ, Mori K, **Lansky AJ**, Mintz GS, Lee MM, Park SJ. Treatment of diffuse in-stent restenosis with drug-eluting stents vs. intracoronary beta-radiation therapy: INDEED Study. *International Journal Of Cardiology* 2008, 131:70-7.
 157. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, **Lansky AJ**. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. *JAMA* 2008, 299:1903-13.
 158. Dangas G, Stone GW, Weinberg MD, Webb J, Cox DA, Brodie BR, Krucoff MW, Gibbons RJ, **Lansky AJ**, Mehran R. Contemporary outcomes of rescue percutaneous coronary intervention for acute myocardial infarction: comparison with primary angioplasty and the role of distal protection devices (EMERALD trial). *American Heart Journal* 2008, 155:1090-6.
 159. Mehran R, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, Dangas G, Feit F, Ohman EM, Parise H, Fahy M, **Lansky AJ**, Stone GW. The Harmonizing Outcomes with RevascularizatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. *American Heart Journal* 2008, 156:44-56.
 160. Solinas E, Dangas G, Kirtane AJ, **Lansky AJ**, Franklin-Bond T, Boland P, Syros G, Kim YH, Gupta A, Mintz G, Fahy M, Collins M, Kodali S, Stone GW, Moses JW, Leon MB, Mehran R. Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention. *The American Journal Of Cardiology* 2008, 102:311-5.
 161. **Lansky AJ**, Tsuchiya Y, Brener M, Mehran R, Cristea E, Pietras C, Grines CL, Cox DA, Garcia E, Tcheng JE, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Leon MB, Moses J, Stone GW. Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2008, 72:917-24.
 162. Tsujita K, Maehara A, Mintz GS, Doi H, Kubo T, Castellanos C, Liu J, Yang J, Oviedo C, Franklin-Bond T, Dasgupta N, Biro S, Dani L, Dangas GD, Mehran R, Kirtane AJ, **Lansky AJ**, Kreps EM, Collins MB, Stone GW, Moses JW, Leon MB. Comparison of angiographic and intravascular ultrasonic detection of myocardial bridging of the left anterior descending coronary artery. *The American Journal Of Cardiology* 2008, 102:1608-13.
 163. Louvard Y, Thomas M, Dzavik V, Hildick-Smith D, Galassi AR, Pan M, Burzotta F, Zelizko M, Dudek D, Ludman P, Sheiban I, Lassen JF, Darremont O, Kastrati A, Ludwig J, Iakovou I, Brunel P, **Lansky A**, Meerkin D, Legrand V, Medina A, Lefèvre T. Classification of coronary artery bifurcation lesions and

- treatments: time for a consensus! Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions 2008, 71:175-83.
164. Aoki J, Kirtane AJ, Dangas GD, **Lansky AJ**, Morales A, Kimura M, Kim YH, Moussa I, Weisz G, Kreps EM, Collins M, Franklin-Bond T, Stone GW, Moses JW, Leon MB, Mehran R. Clinical outcomes after heterogeneous overlap stenting with drug-eluting stents and bare-metal stents for de novo coronary artery narrowings. The American Journal Of Cardiology 2008, 101:58-62.
 165. Pucelikova T, Mehran R, Kirtane AJ, Kim YH, Fahy M, Weisz G, **Lansky AJ**, Moussa I, Gray WA, Collins MB, Kodali SK, Stone GW, Moses JW, Leon MB, Dangas G. Short- and long-term outcomes after stent-assisted percutaneous treatment of saphenous vein grafts in the drug-eluting stent era. The American Journal Of Cardiology 2008, 101:63-8.
 166. White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, Cox DA, Pocock SJ, Ware JA, Manoukian SV, **Lansky AJ**, Mehran R, Moses JW, Stone GW. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUTY (Acute Catheterization and Urgent Intervention Triage strategy) trial. Journal Of The American College Of Cardiology 2008, 52:807-14.
 167. Kim YH, Dangas GD, Solinas E, Aoki J, Parise H, Kimura M, Franklin-Bond T, Dasgupta NK, Kirtane AJ, Moussa I, **Lansky AJ**, Collins M, Stone GW, Leon MB, Moses JW, Mehran R. Effectiveness of drug-eluting stent implantation for patients with unprotected left main coronary artery stenosis. The American Journal Of Cardiology 2008, 101:801-6.
 168. Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, **Lansky AJ**, Fitzgerald PJ, Garg J, Turco MA, Simonton CA, Verheye S, Dubois CL, Gammon R, Batchelor WB, O'Shaughnessy CD, Hermiller JB, Schofer J, Buchbinder M, Wijns W. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. Journal Of The American College Of Cardiology 2008, 51:1543-52.
 169. Kereiakes DJ, Petersen JL, Batchelor WB, Fitzgerald PJ, Mehran R, **Lansky A**, Tsujino I, Schofer J, Dubois C, Verheye S, Cristea E, Garg J, Wijns W, Krucoff MW. Clinical and angiographic outcomes in diabetic patients following single or multivessel stenting in the COSTAR II randomized trial. The Journal Of Invasive Cardiology 2008, 20:335-41.
 170. Liu X, Doi H, Maehara A, Mintz GS, Costa Jde R, Sano K, Weisz G, Dangas GD, **Lansky AJ**, Kreps EM, Collins M, Fahy M, Stone GW, Moses JW, Leon MB, Mehran R. A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis. JACC. Cardiovascular Interventions 2009, 2:428-34.
 171. Stone GW, Martin JL, de Boer MJ, Margheri M, Bramucci E, Blankenship JC, Metzger DC, Gibbons RJ, Lindsay BS, Weiner BH, **Lansky AJ**, Krucoff MW, Fahy M, Boscardin WJ. Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction. Circulation. Cardiovascular Interventions 2009, 2:366-75.
 172. Liu X, Tsujita K, Maehara A, Mintz GS, Weisz G, Dangas GD, **Lansky AJ**, Kreps EM, Rabbani LE, Collins M, Stone GW, Moses JW, Mehran R, Leon MB. Intravascular ultrasound assessment of the incidence and predictors of edge dissections after drug-eluting stent implantation. JACC. Cardiovascular Interventions 2009, 2:997-1004.
 173. Maehara A, Mintz GS, **Lansky AJ**, Witenbichler B, Guagliumi G, Brodie B, Kellett MA, Parise H, Mehran R, Stone GW. Volumetric intravascular ultrasound analysis of Paclitaxel-eluting and bare

- metal stents in acute myocardial infarction: the harmonizing outcomes with revascularization and stents in acute myocardial infarction intravascular ultrasound substudy. *Circulation* 2009, 120:1875-82.
174. Ng VG, **Lansky AJ**. Treatment of left main and multivessel disease in the drug-eluting stent era. *Reviews In Cardiovascular Medicine* 2009, 10 Suppl 2:S24-33.
 175. Verheye S, Agostoni P, Dawkins KD, Dens J, Rutsch W, Carrie D, Schofer J, Lotan C, Dubois CL, Cohen SA, Fitzgerald PJ, **Lansky AJ**. The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) trial. *JACC. Cardiovascular Interventions* 2009, 2:205-14.
 176. Rabbani LE, Iyengar S, Dangas GD, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Stant J, Fahy M, **Lansky AJ**, Mehran R, Stone GW. Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction. *Journal Of Interventional Cardiology* 2009, 22:378-84.
 177. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, **Lansky AJ**, Mehran R, Stone GW. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. *Circulation* 2009, 119:3198-206.
 178. **Lansky AJ**, Ng VG, Mutlu H, Cristea E, Guiran JB, Midei M, Newman W, Sanz M, Sood P, Doostzadeh J, Su X, White R, Cao S, Sudhir K, Stone GW. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2009, 74:719-27.
 179. Prasad A, Gersh BJ, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Pocock SJ, McLaurin BT, Cox DA, **Lansky AJ**, Mehran R, Stone GW. Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. *Journal Of The American College Of Cardiology* 2009, 54:477-86.
 180. Nikolsky E, Mehran R, Sadeghi HM, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, **Lansky AJ**, Stone GW. Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial. *JACC. Cardiovascular Interventions* 2009, 2:624-32.
 181. Mehran R, Nikolsky E, **Lansky AJ**, Kirtane AJ, Kim YH, Feit F, Manoukian S, Moses JW, Ebrahimi R, Ohman EM, White HD, Pocock SJ, Dangas GD, Stone GW. Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) substudy. *JACC. Cardiovascular Interventions* 2009, 2:748-57.
 182. Doll JA, Nikolsky E, Stone GW, Mehran R, Lincoff AM, Caixeta A, McLaurin B, Cristea E, Fahy M, Kesanakurthy V, **Lansky AJ**. Outcomes of patients with coronary artery perforation complicating percutaneous coronary intervention and correlations with the type of adjunctive antithrombotic therapy: pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials. *Journal Of Interventional Cardiology* 2009, 22:453-9.

183. Caixeta A, Leon MB, **Lansky AJ**, Nikolsky E, Aoki J, Moses JW, Schofer J, Morice MC, Schampaert E, Kirtane AJ, Popma JJ, Parise H, Fahy M, Mehran R. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. *Journal Of The American College Of Cardiology* 2009, 54:894-902.
184. Mehran R, **Lansky AJ**, Witzienbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. *Lancet* 2009, 374:1149-59.
185. Nikolsky E, Stone GW, Lee E, **Lansky AJ**, Webb J, Cox DA, Brodie BR, Turco MA, Rutherford BD, Kalynych AM, Antoniucci D, Krucoff MW, Gibbons RJ, Fahy M, Mehran R. Correlations between epicardial flow, microvascular reperfusion, infarct size and clinical outcomes in patients with anterior versus non-anterior myocardial infarction treated with primary or rescue angioplasty: analysis from the EMERALD trial. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2009, 5:417-24.
186. Nikolsky E, Stone GW, Kirtane AJ, Dangas GD, **Lansky AJ**, McLaurin B, Lincoff AM, Feit F, Moses JW, Fahy M, Manoukian SV, White HD, Ohman EM, Bertrand ME, Cox DA, Mehran R. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUTY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. *Journal Of The American College Of Cardiology* 2009, 54:1293-302.
187. Tsujita K, Maehara A, Mintz GS, Kubo T, Doi H, **Lansky AJ**, Stone GW, Moses JW, Leon MB, Ochiai M. Intravascular ultrasound comparison of the retrograde versus antegrade approach to percutaneous intervention for chronic total coronary occlusions. *JACC. Cardiovascular Interventions* 2009, 2:846-54.
188. Nikolsky E, **Lansky AJ**, Sudhir K, Doostzadeh J, Cutlip DE, Piana R, Su X, White R, Simonton CA, Stone GW. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. *American Heart Journal* 2009, 158:520-526.e2.
189. Verheye S, Agostoni P, Dubois CL, Dens J, Ormiston J, Worthley S, Trauthen B, Hasegawa T, Koo BK, Fitzgerald PJ, Mehran R, **Lansky AJ**. 9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study. *Journal Of The American College Of Cardiology* 2009, 53:1031-9.
190. Mehran R, Pocock SJ, Stone GW, Clayton TC, Dangas GD, Feit F, Manoukian SV, Nikolsky E, **Lansky AJ**, Kirtane A, White HD, Colombo A, Ware JH, Moses JW, Ohman EM. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUTY trial. *European Heart Journal* 2009, 30:1457-66.
191. **Lansky AJ**, Mehran R, Cristea E, Parise H, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Stone GW. Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUTY trial). *The American Journal Of Cardiology* 2009, 103:1196-203.

192. Stone GW, **Lansky AJ**, Pocock SJ, Gersh BJ, Dangas G, Wong SC, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Ochala A, Kellock A, Parise H, Mehran R. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. *The New England Journal Of Medicine* 2009, 360:1946-59.
193. Tsujita K, Maehara A, Mintz GS, Doi H, Kubo T, Castellanos C, Liu J, Yang J, Oviedo C, Franklin-Bond T, Sugirtharaj DD, Dangas GD, **Lansky AJ**, Stone GW, Moses JW, Leon MB, Mehran R. Impact of myocardial bridge on clinical outcome after coronary stent placement. *The American Journal Of Cardiology* 2009, 103:1344-8.
194. **Lansky A**, Tuinenburg J, Costa M, Maeng M, Koning G, Popma J, Cristea E, Gavit L, Costa R, Rares A, Van Es GA, Lefevre T, Reiber H, Louvard Y, Morice MC. Quantitative angiographic methods for bifurcation lesions: a consensus statement from the European Bifurcation Group. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2009, 73:258-66.
195. Aoki J, **Lansky AJ**, Mehran R, Moses J, Bertrand ME, McLaurin BT, Cox DA, Lincoff AM, Ohman EM, White HD, Parise H, Leon MB, Stone GW. Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. *Circulation* 2009, 119:687-98.
196. Doi H, Maehara A, Mintz GS, Tsujita K, Kubo T, Castellanos C, Liu J, Yang J, Oviedo C, Aoki J, Franklin-Bond T, Dasgupta N, **Lansky AJ**, Dangas GD, Stone GW, Moses JW, Mehran R, Leon MB. Classification and potential mechanisms of intravascular ultrasound patterns of stent fracture. *The American Journal Of Cardiology* 2009, 103:818-23.
197. Goto K, **Lansky AJ**, Fahy M, Cristea E, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Mehran R, Stone GW. Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy. *Circulation* 2010, 121:853-62.
198. **Lansky AJ**, Goto K, Cristea E, Fahy M, Parise H, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Mehran R, Moses J, Leon M, Stone GW. Clinical and angiographic predictors of short- and long-term ischemic events in acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. *Circulation. Cardiovascular Interventions* 2010, 3:308-16.
199. Applegate RJ, Hermiller JJ, Sanz M, Doostzadeh J, Pierson W, Su X, **Lansky AJ**, Sudhir K, Stone GW. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2010, 6:437-46.
200. Stone GW, Parise H, Witzenbichler B, Kirtane A, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, **Lansky AJ**, Mehran R. Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. *Journal Of The American College Of Cardiology* 2010, 56:1597-604.
201. Rosenberg S, Elashoff MR, Beineke P, Daniels SE, Wingrove JA, Tingley WG, Sager PT, Sehnert AJ, Yau M, Kraus WE, Newby LK, Schwartz RS, Voros S, Ellis SG, Tahirkheli N, Waksman R, McPherson J, **Lansky A**, Winn ME, Schork NJ, Topol EJ. Multicenter validation of the diagnostic accuracy of a

- blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. *Annals Of Internal Medicine* 2010, 153:425-34.
202. Ben-Gal Y, Moses JW, Mehran R, **Lansky AJ**, Weisz G, Nikolsky E, Argenziano M, Williams MR, Colombo A, Aylward PE, Stone GW. Surgical versus percutaneous revascularization for multivessel disease in patients with acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. *JACC. Cardiovascular Interventions* 2010, 3:1059-67.
 203. **Lansky AJ**, Yaqub M, Hermiller JB, Smith RS, Farhat N, Caputo R, Williams JE, Sanz M, Koo K, Sood P, Sudhir K, Stone GW. Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2010, 6 Suppl J:J44-52.
 204. Pocock SJ, Mehran R, Clayton TC, Nikolsky E, Parise H, Fahy M, **Lansky AJ**, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Stone GW. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. *Circulation* 2010, 121:43-51.
 205. Saltzman AJ, Mehran R, Hooper WC, Moses JW, Weisz G, Collins MB, **Lansky AJ**, Kreps EM, Leon MB, Stone GW, Dangas G. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention. *The Journal Of Invasive Cardiology* 2010, 22:2-6.
 206. Oviedo C, Maehara A, Mintz GS, Araki H, Choi SY, Tsujita K, Kubo T, Doi H, Templin B, **Lansky AJ**, Dangas G, Leon MB, Mehran R, Tahk SJ, Stone GW, Ochiai M, Moses JW. Intravascular ultrasound classification of plaque distribution in left main coronary artery bifurcations: where is the plaque really located? *Circulation. Cardiovascular Interventions* 2010, 3:105-12.
 207. Tsujita K, Maehara A, Mintz GS, **Lansky AJ**, Kubo T, Doi H, Yang J, Bharaj H, Witzenbichler B, Guagliumi G, Brodie BR, Kellett MA, Parise H, Mehran R, Stone GW. Serial intravascular ultrasound analysis of the impact of myocardial bridge on neointimal proliferation after coronary stenting in patients with acute myocardial infarction. *Journal Of Interventional Cardiology* 2010, 23:114-22.
 208. Oviedo C, Maehara A, Mintz GS, Tsujita K, Kubo T, Doi H, Castellanos C, **Lansky AJ**, Mehran R, Dangas G, Leon MB, Stone GW, Templin B, Araki H, Ochiai M, Moses JW. Is accurate intravascular ultrasound evaluation of the left circumflex ostium from a left anterior descending to left main pullback possible? *The American Journal Of Cardiology* 2010, 105:948-54.
 209. Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, Stuckey T, Tcheng JE, Mehran R, **Lansky AJ**, Grines CL, Stone GW. Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. *Journal Of The American College Of Cardiology* 2010, 55:1416-24.
 210. Blankenship JC, Skelding KA, Scott TD, Berger PB, Parise H, Brodie BR, Witzenbichler B, Gaugliumi G, Peruga JZ, **Lansky AJ**, Mehran R, Stone GW. Predictors of reperfusion delay in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention from the HORIZONS-AMI trial. *The American Journal Of Cardiology* 2010, 106:1527-33.
 211. **Lansky AJ**, Stone GW. Periprocedural myocardial infarction: prevalence, prognosis, and prevention. *Circulation. Cardiovascular Interventions* 2010, 3:602-10.
 212. Caixeta A, **Lansky AJ**, Serruys PW, Hermiller JB, Ruygrok P, Onuma Y, Gordon P, Yaqub M, Miquel-Hebert K, Veldhof S, Sood P, Su X, Jonnavithula L, Sudhir K, Stone GW. Clinical follow-up 3 years

- after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials. *JACC. Cardiovascular Interventions* 2010, 3:1220-8.
213. Kereiakes DJ, Sudhir K, Hermiller JB, Gordon PC, Ferguson J, Yaqub M, Sood P, Su X, Yakubov S, **Lansky AJ**, Stone GW. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials. *JACC. Cardiovascular Interventions* 2010, 3:1229-39.
 214. Kirtane AJ, Parise H, Mehran R, Moses JW, Fahy M, Bertrand ME, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Ware JH, Pocock SJ, **Lansky AJ**, Stone GW. Comparison of catheterization laboratory initiated abciximab and eptifibatide during percutaneous coronary intervention in acute coronary syndromes (an ACUITY substudy). *The American Journal Of Cardiology* 2010, 106:180-6.
 215. Brodie BR, Gersh BJ, Stuckey T, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Grines CL, Cox D, Parise H, Prasad A, **Lansky AJ**, Mehran R, Stone GW. When is door-to-balloon time critical? Analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trials. *Journal Of The American College Of Cardiology* 2010, 56:407-13.
 216. Parodi G, Antoniucci D, Nikolsky E, Witzenbichler B, Guagliumi G, Peruga JZ, Stuckey T, Dudek D, Kornowski R, Hartmann F, **Lansky AJ**, Mehran R, Stone GW. Impact of bivalirudin therapy in high-risk patients with acute myocardial infarction: 1-year results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. *JACC. Cardiovascular Interventions* 2010, 3:796-802.
 217. Guo N, Maehara A, Mintz GS, He Y, Xu K, Wu X, **Lansky AJ**, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA, Dressler O, Parise H, Mehran R, Stone GW. Incidence, mechanisms, predictors, and clinical impact of acute and late stent malapposition after primary intervention in patients with acute myocardial infarction: an intravascular ultrasound substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. *Circulation* 2010, 122:1077-84.
 218. Doi H, Maehara A, Mintz GS, Tsujita K, Kubo T, Castellanos C, **Lansky AJ**, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA, Parise H, Mehran R, Leon MB, Moses JW, Stone GW. Intravascular ultrasound findings of stent fractures in patients with Sirolimus- and Paclitaxel-eluting stents. *The American Journal Of Cardiology* 2010, 106:952-7.
 219. Gordon PC, Applegate RJ, Hermiller JB, Weinsier SB, Doostzadeh J, Cao S, Sudhir K, **Lansky AJ**, Stone GW. Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: the SPIRIT III 4.0 mm registry. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2010, 75:179-86.

220. Janssen JP, Rares A, Tuinenburg JC, Koning G, **Lansky AJ**, Reiber JH. New approaches for the assessment of vessel sizes in quantitative (cardio-)vascular X-ray analysis. *The International Journal Of Cardiovascular Imaging* 2010, 26:259-71.
221. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, **Lansky AJ**, Cutlip DE, Kereiakes DJ. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. *The New England Journal Of Medicine* 2010, 362:1663-74.
222. Tsujita K, Nikolsky E, **Lansky AJ**, Dangas G, Fahy M, Brodie BR, Dudek D, Möckel M, Ochala A, Mehran R, Stone GW. Impact of anemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial). *The American Journal Of Cardiology* 2010, 105:1385-94.
223. Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, Dave R, Ansel G, **Lansky A**, Cristea E, Collins TJ, Goldstein J, Jaff MR. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. *Circulation. Cardiovascular Interventions* 2010, 3:267-76.
224. Applegate R, Hermiller J, Williams J, Gordon P, Doostzadeh J, Cao S, Su X, Sudhir K, **Lansky A**, Simonton C, Stone G. Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trial. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2010, 76:644-51.
225. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumi G, **Lansky AJ**, Stone GW. A risk score to predict bleeding in patients with acute coronary syndromes. *Journal Of The American College Of Cardiology* 2010, 55:2556-66.
226. Seth A, Serruys PW, **Lansky A**, Hermiller J, Onuma Y, Miquel-Hebert K, Yu S, Veldhof S, Sood P, Sudhir K, Stone GW. A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2010, 5:788-94.
227. **Lansky A**, Goto K, Fahy M, Cristea E, Mehran R, Stone GW, Feit F, Ohman EM, Alexander KP, White HD, Bertrand ME, Desmet W, Hamon M. Response to letters regarding article, "Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy". *Circulation* 2011, 123:e410-1.
228. Caixeta A, Stone GW, Mehran R, Lee EA, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Ohman EM, Palmerini T, Syros G, Kittas C, Fahy M, Hooper WC, **Lansky AJ**, Dangas GD. Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial. *Journal Of Thrombosis And Thrombolysis* 2011, 31:154-64.
229. Meier P, **Lansky AJ**, McGregor CG. Who should treat coronary left main disease--a battle of the titans? *Cardiology* 2011, 118:233-5.
230. Hermiller JB, Nikolsky E, **Lansky AJ**, Applegate RJ, Sanz M, Yaqub M, Sood P, Cao S, Sudhir K, Stone GW. Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. *EuroIntervention :*

- Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology 2011, 7:307-13.
231. Brener SJ, Mehran R, Brodie BR, Guagliumi G, Witzenbichler B, Cristea E, Xu K, **Lansky AJ**, Stone GW. Predictors and implications of coronary infarct artery patency at initial angiography in patients with acute myocardial infarction (from the CADILLAC and HORIZONS-AMI Trials). The American Journal Of Cardiology 2011, 108:918-23.
 232. Goto K, **Lansky AJ**, Nikolsky E, Fahy M, Feit F, Ohman EM, White HD, Mehran R, Bertrand ME, Desmet W, Hamon M, Stone GW. Prognostic significance of coronary thrombus in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a subanalysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. JACC. Cardiovascular Interventions 2011, 4:769-77.
 233. Kornowski R, Mehran R, Dangas G, Nikolsky E, Assali A, Claessen BE, Gersh BJ, Wong SC, Witzenbichler B, Guagliumi G, Dudek D, Fahy M, **Lansky AJ**, Stone GW. Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. Journal Of The American College Of Cardiology 2011, 58:704-11.
 234. Goto K, Nikolsky E, **Lansky AJ**, Dangas G, Witzenbichler B, Parise H, Guagliumi G, Kornowski R, Claessen BE, Fahy M, Mehran R, Stone GW. Impact of smoking on outcomes of patients with ST-segment elevation myocardial infarction (from the HORIZONS-AMI Trial). The American Journal Of Cardiology 2011, 108:1387-94.
 235. Caixeta A, Dangas GD, Mehran R, Feit F, Nikolsky E, **Lansky AJ**, Aoki J, Moses JW, Steinhubl SR, White HD, Ohman EM, Manoukian SV, Fahy M, Stone GW. Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. American Heart Journal 2011, 161:298-306.e1.
 236. Hakim DA, Dangas GD, Caixeta A, Nikolsky E, **Lansky AJ**, Moses JW, Claessen B, Sanidas E, White HD, Ohman EM, Manoukian SV, Fahy M, Mehran R, Stone GW. Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. American Heart Journal 2011, 161:391-6.
 237. Tuinenburg JC, Koning G, Rareş A, Janssen JP, **Lansky AJ**, Reiber JH. Dedicated bifurcation analysis: basic principles. The International Journal Of Cardiovascular Imaging 2011, 27:167-74.
 238. Ng VG, **Lansky AJ**. Novel QCA methodologies and angiographic scores. The International Journal Of Cardiovascular Imaging 2011, 27:157-65.
 239. Witzenbichler B, Wöhrle J, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Hood KL, Parise H, **Lansky AJ**, Nikolsky E, Mehran R, Stone GW. Paclitaxel-eluting stents compared with bare metal stents in diabetic patients with acute myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. Circulation. Cardiovascular Interventions 2011, 4:130-8.
 240. Gibson CM, Maehara A, **Lansky AJ**, Wöhrle J, Stuckey T, Dave R, Cox D, Grines C, Dudek D, Steg G, Parise H, Wolff SD, Cristea E, Stone GW. Rationale and design of the INFUSE-AMI study: A 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and

- aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. *American Heart Journal* 2011, 161:478-486.e7.
241. Stone GW, Goldberg S, O'Shaughnessy C, Midei M, Siegel RM, Cristea E, Dangas G, **Lansky AJ**, Mehran R. 5-year follow-up of polytetrafluoroethylene-covered stents compared with bare-metal stents in aortocoronary saphenous vein grafts the randomized BARRICADE (barrier approach to restenosis: restrict intima to curtail adverse events) trial. *JACC. Cardiovascular Interventions* 2011, 4:300-9.
 242. Bezenek S, Hermiller J, **Lansky A**, Yaqub M, Hattori K, Cao S, Sood P, Sudhir K. Low stent thrombosis risk with the XIENCE V® Everolimus-Eluting Coronary Stent: evidence from randomized and single-arm clinical trials. *Journal Of Interventional Cardiology* 2011, 24:326-41.
 243. Elashoff MR, Wingrove JA, Beineke P, Daniels SE, Tingley WG, Rosenberg S, Voros S, Kraus WE, Ginsburg GS, Schwartz RS, Ellis SG, Tahirkheli N, Waksman R, McPherson J, **Lansky AJ**, Topol EJ. Development of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patients. *BMC Medical Genomics* 2011, 4:26.
 244. Dangas GD, Caixeta A, Mehran R, Parise H, **Lansky AJ**, Cristea E, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Möeckel M, Stone GW. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. *Circulation* 2011, 123:1745-56.
 245. Choi SY, Witzenbichler B, Maehara A, **Lansky AJ**, Guagliumi G, Brodie B, Kellett MA, Dressler O, Parise H, Mehran R, Dangas GD, Mintz GS, Stone GW. Intravascular ultrasound findings of early stent thrombosis after primary percutaneous intervention in acute myocardial infarction: a Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) substudy. *Circulation. Cardiovascular Interventions* 2011, 4:239-47.
 246. Wu X, Mintz GS, Xu K, **Lansky AJ**, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA, Dressler O, Parise H, Mehran R, Stone GW, Maehara A. The relationship between attenuated plaque identified by intravascular ultrasound and no-reflow after stenting in acute myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. *JACC. Cardiovascular Interventions* 2011, 4:495-502.
 247. Palmerini T, Mehran R, Dangas G, Nikolsky E, Witzenbichler B, Guagliumi G, Dudek D, Genereux P, Caixeta A, Rabbani L, Weisz G, Parise H, Fahy M, Xu K, Brodie B, **Lansky A**, Stone GW. Impact of leukocyte count on mortality and bleeding in patients with myocardial infarction undergoing primary percutaneous coronary interventions: analysis from the Harmonizing Outcome with Revascularization and Stent in Acute Myocardial Infarction trial. *Circulation* 2011, 123:2829-37, 7 p following 2837.
 248. Dangas GD, Mehran R, Nikolsky E, Claessen BE, **Lansky AJ**, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Möckel M, Caixeta A, Parise H, White H, Stone GW. Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis. *Journal Of The American College Of Cardiology* 2011, 57:2309-16.
 249. Palmerini T, Genereux P, Caixeta A, Cristea E, **Lansky A**, Mehran R, Dangas G, Lazar D, Sanchez R, Fahy M, Xu K, Stone GW. Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUTY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. *Journal Of The American College Of Cardiology* 2011, 57:2389-97.

250. Mehran R, Pocock S, Nikolsky E, Dangas GD, Clayton T, Claessen BE, Caixeta A, Feit F, Manoukian SV, White H, Bertrand M, Ohman EM, Parise H, **Lansky AJ**, Lincoff AM, Stone GW. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomas to reduced clinical events), ACUTY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. *JACC. Cardiovascular Interventions* 2011, 4:654-64.
251. Möckel M, Vollert J, **Lansky AJ**, Witzendichler B, Guagliumi G, Peruga JZ, Brodie BR, Kornowski R, Dudek D, Farkouh ME, Parise H, Mehran R, Stone GW. Comparison of direct stenting with conventional stent implantation in acute myocardial infarction. *The American Journal Of Cardiology* 2011, 108:1697-703.
252. Saltzman AJ, Stone GW, Claessen BE, Narula A, Leon-Reyes S, Weisz G, Brodie B, Witzendichler B, Guagliumi G, Kornowski R, Dudek D, Metzger DC, **Lansky AJ**, Nikolsky E, Dangas GD, Mehran R. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. *JACC. Cardiovascular Interventions* 2011, 4:1011-9.
253. Suh JW, Mehran R, Claessen BE, Xu K, Baber U, Dangas G, Parise H, **Lansky AJ**, Witzendichler B, Grines CL, Guagliumi G, Kornowski R, Wöhrle J, Dudek D, Weisz G, Stone GW. Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. *Journal Of The American College Of Cardiology* 2011, 58:1750-6.
254. Shin DH, Koo BK, Waseda K, Park KW, Kim HS, Corral M, **Lansky A**, Honda Y, Fearon WF, Fitzgerald PJ. Discrepancy in the assessment of jailed side branch lesions by visual estimation and quantitative coronary angiographic analysis: comparison with fractional flow reserve. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2011, 78:720-6.
255. Palmerini T, Dangas G, Mehran R, Caixeta A, G  n  reux P, Fahy MP, Xu K, Cristea E, **Lansky AJ**, Stone GW. Predictors and implications of stent thrombosis in non-ST-segment elevation acute coronary syndromes: the ACUTY Trial. *Circulation. Cardiovascular Interventions* 2011, 4:577-84.
256. G  n  reux P, Palmerini T, Caixeta A, Cristea E, Mehran R, Sanchez R, Lazar D, Jankovic I, Corral MD, Dressler O, Fahy MP, Parise H, **Lansky AJ**, Stone GW. SYNTAX score reproducibility and variability between interventional cardiologists, core laboratory technicians, and quantitative coronary measurements. *Circulation. Cardiovascular Interventions* 2011, 4:553-61.
257. Koo BK, Erglis A, Doh JH, Daniels DV, Jegere S, Kim HS, Dunning A, DeFrance T, **Lansky A**, Leipsic J, Min JK. Diagnosis of ischemia-causing coronary stenoses by noninvasive fractional flow reserve computed from coronary computed tomographic angiograms. Results from the prospective multicenter DISCOVER-FLOW (Diagnosis of Ischemia-Causing Stenoses Obtained Via Noninvasive Fractional Flow Reserve) study. *Journal Of The American College Of Cardiology* 2011, 58:1989-97.
258. Claessen BE, Smits PC, Kereiakes DJ, Parise H, Fahy M, Kedhi E, Serruys PW, **Lansky AJ**, Cristea E, Sudhir K, Sood P, Simonton CA, Stone GW. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting

- Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials. *JACC. Cardiovascular Interventions* 2011, 4:1209-15.
259. Brener SJ, Cristea E, Mehran R, Dressler O, **Lansky AJ**, Stone GW. Relationship between angiographic dynamic and densitometric assessment of myocardial reperfusion and survival in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: the harmonizing outcomes with revascularization and stents in AMI (HORIZONS-AMI) trial. *American Heart Journal* 2011, 162:1044-51.
 260. G  n  reux P, Mehran R, Palmerini T, Caixeta A, Kirtane AJ, **Lansky AJ**, Brodie BR, Witzenbichler B, Mockel M, Guagliumi G, Peruga JZ, Dudek D, Fahy MP, Dangas G, Stone GW. Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2011, 7:905-16.
 261. Guagliumi G, Costa MA, Sirbu V, Musumeci G, Bezerra HG, Suzuki N, Matiashvili A, Lortkipanidze N, Mihalcsik L, Trivisonno A, Valsecchi O, Mintz GS, Dressler O, Parise H, Maehara A, Cristea E, **Lansky AJ**, Mehran R, Stone GW. Strut coverage and late malapposition with paclitaxel-eluting stents compared with bare metal stents in acute myocardial infarction: optical coherence tomography substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. *Circulation* 2011, 123:274-81.
 262. Stone GW, Maehara A, **Lansky AJ**, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, Serruys PW. A prospective natural-history study of coronary atherosclerosis. *The New England Journal Of Medicine* 2011, 364:226-35.
 263. Applegate RJ, Yaqub M, Hermiller JB, Sood P, Yu S, Doostzadeh J, Williams JE, Farhat N, Caputo R, **Lansky AJ**, Cutlip DE, Sudhir K, Stone GW. Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial). *The American Journal Of Cardiology* 2011, 107:833-40.
 264. Ng VG, **Lansky AJ**, Hermiller JB, Farhat N, Applegate RJ, Yaqub M, Sood P, Su X, Simonton CA, Sudhir K, Stone GW. Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial). *The American Journal Of Cardiology* 2011, 107:841-8.
 265. Ruiz-Garc  a J, Lerman A, Weisz G, Maehara A, Mintz GS, Fahy M, Xu K, **Lansky AJ**, Cristea E, Farah TG, Teles R, Botker HE, Templin B, Zhang Z, de Bruyne B, Serruys PW, Stone GW. Age- and gender-related changes in plaque composition in patients with acute coronary syndrome: the PROSPECT study. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2012, 8:929-38.
 266. Yu J, Mehran R, Dangas GD, Claessen BE, Baber U, Xu K, Parise H, Fahy M, **Lansky AJ**, Witzenbichler B, Grines CL, Guagliumi G, Kornowski R, W  hrle J, Dudek D, Weisz G, Stone GW. Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. *JACC. Cardiovascular Interventions* 2012, 5:1231-8.
 267. Bansilal S, Farkouh ME, Hueb W, Ogdie M, Dangas G, **Lansky AJ**, Cohen DJ, Magnuson EA, Ramanathan K, Tanguay JF, Muratov V, Sleeper LA, Domanski M, Bertrand ME, Fuster V. The Future

- REvascularization Evaluation in patients with Diabetes mellitus: optimal management of Multivessel disease (FREEDOM) trial: clinical and angiographic profile at study entry. *American Heart Journal* 2012, 164:591-9.
268. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, **Lansky A**, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S, Bertrand M, Fuster V. Strategies for multivessel revascularization in patients with diabetes. *The New England Journal Of Medicine* 2012, 367:2375-84.
 269. Palmerini T, Genereux P, Caixeta A, Cristea E, **Lansky A**, Mehran R, Della Riva D, Fahy M, Xu K, Stone GW. A new score for risk stratification of patients with acute coronary syndromes undergoing percutaneous coronary intervention: the ACUITY-PCI (Acute Catheterization and Urgent Intervention Triage Strategy-Percutaneous Coronary Intervention) risk score. *JACC. Cardiovascular Interventions* 2012, 5:1108-16.
 270. Whitlow PL, Burke MN, Lombardi WL, Wyman RM, Moses JW, Brilakis ES, Heuser RR, Rihal CS, **Lansky AJ**, Thompson CA. Use of a novel crossing and re-entry system in coronary chronic total occlusions that have failed standard crossing techniques: results of the FAST-CTOs (Facilitated Antegrade Steering Technique in Chronic Total Occlusions) trial. *JACC. Cardiovascular Interventions* 2012, 5:393-401.
 271. Golinvaux N, Maehara A, Mintz GS, **Lansky AJ**, McPherson J, Farhat N, Marso S, de Bruyne B, Serruys PW, Templin B, Cheong WF, Aaskar R, Fahy M, Mehran R, Leon M, Stone GW. An intravascular ultrasound appraisal of atherosclerotic plaque distribution in diseased coronary arteries. *American Heart Journal* 2012, 163:624-31.
 272. Rosner GF, Kirtane AJ, Genereux P, **Lansky AJ**, Cristea E, Gersh BJ, Weisz G, Parise H, Fahy M, Mehran R, Stone GW. Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. *Circulation* 2012, 125:2613-20.
 273. Dangas GD, Claessen BE, Mehran R, Brener S, Brodie BR, Dudek D, Witzenbichler B, Peruga JZ, Guagliumi G, Moses JW, **Lansky AJ**, Xu K, Stone GW. Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. *Journal Of The American College Of Cardiology* 2012, 59:1752-9.
 274. Qian J, Xu B, **Lansky AJ**, Yang YJ, Qiao SB, Wu YJ, Chen J, Hu FH, Yang WX, Mintz GS, Leon MB, Gao RL. First report of a novel abluminal groove filled biodegradable polymer rapamycin-eluting stent in de novo coronary artery disease: results of the first in man FIREHAWK trial. *Chinese Medical Journal* 2012, 125:970-6.
 275. Nolan JP, Lyon RM, Sasson C, Rossetti AO, **Lansky AJ**, Fox KA, Meier P. Advances in the hospital management of patients following an out of hospital cardiac arrest. *Heart (British Cardiac Society)* 2012, 98:1201-6.
 276. Meier P, Indermuehle A, Pitt B, Traupe T, de Marchi SF, Crake T, Knapp G, **Lansky AJ**, Seiler C. Coronary collaterals and risk for restenosis after percutaneous coronary interventions: a meta-analysis. *BMC Medicine* 2012, 10:62.
 277. Min JK, Koo BK, Erglis A, Doh JH, Daniels DV, Jegere S, Kim HS, Dunning AM, Defrance T, **Lansky A**, Leipsic J. Usefulness of noninvasive fractional flow reserve computed from coronary computed

- tomographic angiograms for intermediate stenoses confirmed by quantitative coronary angiography. *The American Journal Of Cardiology* 2012, 110:971-6.
278. Brener SJ, Cristea E, **Lansky AJ**, Fahy M, Mehran R, Stone GW. Operator versus core laboratory assessment of angiographic reperfusion markers in patients undergoing primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction. *Circulation. Cardiovascular Interventions* 2012, 5:563-9.
 279. Saito S, Nakamura S, Fujii K, Nakamura M, Isshiki T, Hirayama H, Kikuchi T, Fujita H, Nonogi H, Mitsudo K, Kimura T, Igarashi K, Saito K, **Lansky AJ**, Stone GW, Honda Y, Waseda K, Fitzgerald PJ, Sudhir K. Mid-term results of everolimus-eluting stent in a Japanese population compared with a US randomized cohort: SPIRIT III Japan Registry with harmonization by doing. *The Journal Of Invasive Cardiology* 2012, 24:444-50.
 280. **Lansky A**, Elashoff MR, Ng V, McPherson J, Lazar D, Kraus WE, Voros S, Schwartz RS, Topol EJ. A gender-specific blood-based gene expression score for assessing obstructive coronary artery disease in nondiabetic patients: results of the Personalized Risk Evaluation and Diagnosis in the Coronary Tree (PREDICT) trial. *American Heart Journal* 2012, 164:320-6.
 281. Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, Dave R, Ansel G, **Lansky A**, Cristea E, Collins TJ, Goldstein J, Cao AY, Jaff MR. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. *Journal Of Endovascular Therapy : An Official Journal Of The International Society Of Endovascular Specialists* 2012, 19:1-9.
 282. Acharji S, Baber U, Mehran R, Fahy M, Kirtane AJ, **Lansky AJ**, Stone GW. Prognostic significance of elevated baseline troponin in patients with acute coronary syndromes and chronic kidney disease treated with different antithrombotic regimens: a substudy from the ACUITY trial. *Circulation. Cardiovascular Interventions* 2012, 5:157-65.
 283. Rosenberg S, Elashoff MR, Lieu HD, Brown BO, Kraus WE, Schwartz RS, Voros S, Ellis SG, Waksman R, McPherson JA, **Lansky AJ**, Topol EJ. Whole blood gene expression testing for coronary artery disease in nondiabetic patients: major adverse cardiovascular events and interventions in the PREDICT trial. *Journal Of Cardiovascular Translational Research* 2012, 5:366-74.
 284. Maehara A, Cristea E, Mintz GS, **Lansky AJ**, Dressler O, Biro S, Templin B, Virmani R, de Bruyne B, Serruys PW, Stone GW. Definitions and methodology for the grayscale and radiofrequency intravascular ultrasound and coronary angiographic analyses. *JACC. Cardiovascular Imaging* 2012, 5:S1-9.
 285. Wykrzykowska JJ, Mintz GS, Garcia-Garcia HM, Maehara A, Fahy M, Xu K, Inguez A, Fajadet J, **Lansky A**, Templin B, Zhang Z, de Bruyne B, Weisz G, Serruys PW, Stone GW. Longitudinal distribution of plaque burden and necrotic core-rich plaques in nonculprit lesions of patients presenting with acute coronary syndromes. *JACC. Cardiovascular Imaging* 2012, 5:S10-8.
 286. Marso SP, Mercado N, Maehara A, Weisz G, Mintz GS, McPherson J, Schiele F, Dudek D, Fahy M, Xu K, **Lansky A**, Templin B, Zhang Z, de Bruyne B, Serruys PW, Stone GW. Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes. *JACC. Cardiovascular Imaging* 2012, 5:S42-52.
 287. Baber U, Stone GW, Weisz G, Moreno P, Dangas G, Maehara A, Mintz GS, Cristea E, Fahy M, Xu K, **Lansky AJ**, Wennerblom B, Mathey DG, Templin B, Zhang Z, Serruys PW, Mehran R. Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes. *JACC. Cardiovascular Imaging* 2012, 5:S53-61.

288. **Lansky AJ**, Ng VG, Maehara A, Weisz G, Lerman A, Mintz GS, De Bruyne B, Farhat N, Niess G, Jankovic I, Lazar D, Xu K, Fahy M, Serruys PW, Stone GW. Gender and the extent of coronary atherosclerosis, plaque composition, and clinical outcomes in acute coronary syndromes. *JACC. Cardiovascular Imaging* 2012, 5:S62-72.
289. McPherson JA, Maehara A, Weisz G, Mintz GS, Cristea E, Mehran R, Foster M, Verheye S, Rabbani L, Xu K, Fahy M, Templin B, Zhang Z, **Lansky AJ**, de Bruyne B, Serruys PW, Stone GW. Residual plaque burden in patients with acute coronary syndromes after successful percutaneous coronary intervention. *JACC. Cardiovascular Imaging* 2012, 5:S76-85.
290. Brener SJ, Mintz GS, Cristea E, Weisz G, Maehara A, McPherson JA, Marso SP, Farhat N, Botker HE, Dressler O, Xu K, Templin B, Zhang Z, **Lansky AJ**, de Bruyne B, Serruys PW, Stone GW. Characteristics and clinical significance of angiographically mild lesions in acute coronary syndromes. *JACC. Cardiovascular Imaging* 2012, 5:S86-94.
291. Sanidas EA, Mintz GS, Maehara A, Cristea E, Wennerblom B, Iñiguez A, Fajadet J, Fahy M, Dressler O, Weisz G, Templin B, Zhang Z, **Lansky AJ**, de Bruyne B, Serruys P, Stone GW. Adverse cardiovascular events arising from atherosclerotic lesions with and without angiographic disease progression. *JACC. Cardiovascular Imaging* 2012, 5:S95-S105.
292. Palmerini T, Caixeta A, Genereux P, Cristea E, **Lansky A**, Mehran R, Dangas G, Lazar D, Sanchez R, Fahy M, Xu K, Stone GW. Comparison of clinical and angiographic prognostic risk scores in patients with acute coronary syndromes: Analysis from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. *American Heart Journal* 2012, 163:383-91, 391.e1-5.
293. **Lansky AJ**, Brar SS, Yaqub M, Sood P, Applegate RJ, Lazar D, Jankovic I, Hermiller JB, Koo K, Sudhir K, Stone GW. Impact of routine angiographic follow-up after percutaneous coronary intervention with drug-eluting stents in the SPIRIT III randomized trial at three years. *The American Journal Of Cardiology* 2012, 110:21-9.
294. Meier P, Hemingway H, **Lansky AJ**, Knapp G, Pitt B, Seiler C. The impact of the coronary collateral circulation on mortality: a meta-analysis. *European Heart Journal* 2012, 33:614-21.
295. Choi SY, Maehara A, Cristea E, Witzienbichler B, Guagliumi G, Brodie B, Kellett MA, Dressler O, **Lansky AJ**, Parise H, Mehran R, Mintz GS, Stone GW. Usefulness of minimum stent cross sectional area as a predictor of angiographic restenosis after primary percutaneous coronary intervention in acute myocardial infarction (from the HORIZONS-AMI Trial IVUS substudy). *The American Journal Of Cardiology* 2012, 109:455-60.
296. Whitlow PL, Lombardi WL, Araya M, Michael Wyman R, Torres H, Dauvergne C, Tsuchikane E, **Lansky A**, Thompson CA. Initial experience with a dedicated coronary re-entry device for revascularization of chronic total occlusions. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2012, 80:807-13.
297. Meier P, Windecker S, **Lansky AJ**. Radial versus femoral access for primary percutaneous coronary intervention: is there a preferred route to the heart? *Heart (British Cardiac Society)* 2012, 98:269-70.
298. Ng VG, **Lansky AJ**. Interventions for ST Elevation Myocardial Infarction in Women. *Interventional Cardiology Clinics* 2012, 1:453-465.
299. Ng VG, **Lansky AJ**. The Generations of Drug-Eluting Stents and Outcomes in Women. *Interventional Cardiology Clinics* 2012, 1:183-195.
300. Nallamothu BK, Spertus JA, **Lansky AJ**, Cohen DJ, Jones PG, Kureshi F, Dehmer GJ, Drozda JP, Walsh MN, Brush JE, Koenig GC, Waites TF, Gantt DS, Kichura G, Chazal RA, O'Brien PK, Valentine CM,

- Rumsfeld JS, Reiber JH, Elmore JG, Krumholz RA, Weaver WD, Krumholz HM. Comparison of clinical interpretation with visual assessment and quantitative coronary angiography in patients undergoing percutaneous coronary intervention in contemporary practice: the Assessing Angiography (A2) project. *Circulation* 2013, 127:1793-800.
301. Meier P, Messerli FH, Baumbach A, **Lansky AJ**. Pre-hypertension: another 'pseudodisease'? *BMC Medicine* 2013, 11:211.
302. Nallamothu BK, Spertus JA, **Lansky AJ**, Cohen DJ, Jones PG, Kureshi F, Dehmer GJ, Drozda JP, Walsh MN, Brush JE, Koenig GC, Waites TF, Gantt DS, Kichura G, Chazal RA, O'Brien PK, Valentine CM, Rumsfeld JS, Reiber JH, Elmore JG, Krumholz RA, Weaver WD, Krumholz HM. Response to letters regarding article, "comparison of clinical interpretation with visual assessment and quantitative coronary angiography in patients undergoing percutaneous coronary intervention in contemporary practice: the assessing angiography (A2) project". *Circulation* 2013, 128:e463-4.
303. Meier P, **Lansky AJ**, Baumbach A. Almanac 2013: acute coronary syndromes. *Anadolu Kardiyoloji Dergisi : AKD = The Anatolian Journal Of Cardiology* 2013, 13:825-32.
304. Banai S, Finkelstein A, Almagor Y, Assali A, Hasin Y, Rosenschein U, Apruzzese P, **Lansky AJ**, Kume T, Edelman ER. Targeted anti-inflammatory systemic therapy for restenosis: the Biores Liposomal Alendronate with Stenting sTudy (BLAST)-a double blind, randomized clinical trial. *American Heart Journal* 2013, 165:234-40.e1.
305. Meller SM, Baumbach A, Voros S, Mullen M, **Lansky AJ**. Challenges in cardiac device innovation: is neuroimaging an appropriate endpoint? Consensus from the 2013 Yale-UCL Cardiac Device Innovation Summit. *BMC Medicine* 2013, 11:257.
306. Meier P, **Lansky AJ**, Baumbach A. Almanac 2013: acute coronary syndromes. *Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir* 2013, 41:755-64.
307. Xu B, Gao RL, Zhang RY, Wang HC, Li ZQ, Yang YJ, Ma CS, Han YL, **Lansky AJ**, Huo Y, Li W, Leon MB. Efficacy and safety of FIREHAWK® abluminal groove filled biodegradable polymer sirolimus-eluting stents for the treatment of long coronary lesions: nine-month angiographic and one-year clinical results from TARGET I trial long cohort. *Chinese Medical Journal* 2013, 126:1026-32.
308. Meier P, **Lansky AJ**, Baumbach A. Almanac 2013: acute coronary syndromes. *Heart (British Cardiac Society)* 2013, 99:1488-93.
309. Gao RL, Xu B, **Lansky AJ**, Yang YJ, Ma CS, Han YL, Chen SL, Li H, Zhang RY, Fu GS, Yuan ZY, Jiang H, Huo Y, Li W, Zhang YJ, Leon MB. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2013, 9:75-83.
310. Meier P, Fröhlich GM, Meller S, De Palma R, **Lansky AJ**. Selection and timing for invasive therapy in non-ST-segment-elevation acute coronary syndrome. *Expert Review Of Cardiovascular Therapy* 2013, 11:437-45.
311. Ng VG, Meller S, Shetty S, **Lansky AJ**. Diagnosing and characterizing coronary artery disease in women: developments in noninvasive and invasive imaging techniques. *Journal Of Cardiovascular Translational Research* 2013, 6:740-51.
312. Forrest JK, **Lansky AJ**, Meller SM, Hou L, Sood P, Applegate RJ, Wang JC, Skelding KA, Shah A, Kereiakes DJ, Sudhir K, Cristea E, Yaqub M, Stone GW. Evaluation of XIENCE V everolimus-eluting

- and Taxus Express2 paclitaxel-eluting coronary stents in patients with jailed side branches from the SPIRIT IV trial at 2 years. *The American Journal Of Cardiology* 2013, 111:1580-6.
313. Meller SM, **Lansky AJ**, Costa RA, Soffler M, Costantini CO, Brodie BR, Cox DA, Stuckey TD, Fahy M, Grines CL, Stone GW. Implications of myocardial reperfusion on survival in women versus men with acute myocardial infarction undergoing primary coronary intervention. *The American Journal Of Cardiology* 2013, 112:1087-92.
 314. Larsen AI, Nilsen DW, Yu J, Mehran R, Nikolsky E, **Lansky AJ**, Caixeta A, Parise H, Fahy M, Cristea E, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Stone GW. Long-term prognosis of patients presenting with ST-segment elevation myocardial infarction with no significant coronary artery disease (from the HORIZONS-AMI trial). *The American Journal Of Cardiology* 2013, 111:643-8.
 315. Indermuehle A, Bahl R, **Lansky AJ**, Froehlich GM, Knapp G, Timmis A, Meier P. Drug-eluting balloon angioplasty for in-stent restenosis: a systematic review and meta-analysis of randomised controlled trials. *Heart (British Cardiac Society)* 2013, 99:327-33.
 316. Dudek D, Mehran R, Dziewierz A, Witzenbichler B, Brodie BR, Kornowski R, Fahy M, **Lansky AJ**, Rakowski T, Legutko J, Bryniarski L, Stone GW. Impact of advanced age on the safety and effectiveness of paclitaxel-eluting stent implantation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: The HORIZONS-AMI trial. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2013, 82:869-77.
 317. Thomas GS, Voros S, McPherson JA, **Lansky AJ**, Winn ME, Bateman TM, Elashoff MR, Lieu HD, Johnson AM, Daniels SE, Ladapo JA, Phelps CE, Douglas PS, Rosenberg S. A blood-based gene expression test for obstructive coronary artery disease tested in symptomatic nondiabetic patients referred for myocardial perfusion imaging the COMPASS study. *Circulation. Cardiovascular Genetics* 2013, 6:154-62.
 318. Caixeta A, **Lansky AJ**, Mehran R, Brener SJ, Claessen B, G  n  reux P, Palmerini T, Witzenbichler B, Guagliumi G, Brodie BR, Dudek D, Fahy M, Dangas GD, Stone GW. Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2013, 9:220-7.
 319. Rakowski T, Dudek D, Dziewierz A, Yu J, Witzenbichler B, Guagliumi G, Kornowski R, Hartmann F, **Lansky AJ**, Brener SJ, Mehran R, Stone GW. Impact of infarct-related artery patency before primary PCI on outcome in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2013, 8:1307-14.
 320. Farkouh ME, Reiffel J, Dressler O, Nikolsky E, Parise H, Cristea E, Baran DA, Dizon J, Merab JP, **Lansky AJ**, Mehran R, Stone GW. Relationship between ST-segment recovery and clinical outcomes after primary percutaneous coronary intervention: the HORIZONS-AMI ECG substudy report. *Circulation. Cardiovascular Interventions* 2013, 6:216-23.
 321. Fr  hlich GM, **Lansky AJ**, Ko DT, Archangelidi O, De Palma R, Timmis A, Meier P. Drug eluting balloons for de novo coronary lesions - a systematic review and meta-analysis. *BMC Medicine* 2013, 11:123.
 322. Obonska K, Navarese EP, **Lansky A**, Tarantini G, Rossini R, Kozinski M, Musumeci G, Di Pasquale G, G  rny B, Szczesniak A, Kowalewski M, Gurbel PA, Kubica J. Low-dose of oral factor Xa inhibitors in

- patients with a recent acute coronary syndrome: a systematic review and meta-analysis of randomized trials. *Atherosclerosis* 2013, 229:482-8.
323. Meier P, **Lansky AJ**. Optimal duration of clopidogrel therapy: the shorter the longer? *European Heart Journal* 2013, 34:1705-7.
 324. Boden WE, **Lansky A**, Angiolillo DJ. Refining the role of antiplatelet therapy in medically managed patients with acute coronary syndrome. *The American Journal Of Cardiology* 2013, 111:439-44.
 325. Tuinenburg JC, Janssen JP, Kooistra R, Koning G, Corral MD, **Lansky AJ**, Reiber JH. Clinical validation of the new T- and Y-shape models for the quantitative analysis of coronary bifurcations: an interobserver variability study. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2013, 81:E225-36.
 326. Wu X, Maehara A, He Y, Xu K, Oviedo C, Witzensbichler B, **Lansky AJ**, Dressler O, Parise H, Stone GW, Mintz GS. Plaque shift and distal embolism in patients with acute myocardial infarction: a volumetric intravascular ultrasound analysis from the HORIZONS-AMI trial. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2013, 82:203-9.
 327. Meier P, Schirmer SH, **Lansky AJ**, Timmis A, Pitt B, Seiler C. The collateral circulation of the heart. *BMC Medicine* 2013, 11:143.
 328. Meier P, Fröhlich GM, **Lansky AJ**. Bleeding complications in percutaneous coronary interventions. *Cardiology* 2013, 125:213-6.
 329. Dohi T, Mintz GS, McPherson JA, de Bruyne B, Farhat NZ, **Lansky AJ**, Mehran R, Weisz G, Xu K, Stone GW, Maehara A. Non-fibroatheroma lesion phenotype and long-term clinical outcomes: a substudy analysis from the PROSPECT study. *JACC. Cardiovascular Imaging* 2013, 6:908-16.
 330. Meier P, Wolfrum M, Froehlich GM, Casaubon LK, **Lansky AJ**. [Not Available]. *Heart (British Cardiac Society)* 2013, 99:1543.
 331. Meier P, Franzen O, **Lansky AJ**. Almanac 2013: novel non-coronary cardiac interventions. *Heart (British Cardiac Society)* 2013, 99:1309-16.
 332. Bahl R, Indermuehle A, Froehlich GM, **Lansky AJ**, Knapp G, Timmis A, Meier P. Drug-eluting balloon for instent restenosis--the author's reply. *Heart (British Cardiac Society)* 2013, 99:1874-5.
 333. De Luca G, Brener SJ, Mehran R, **Lansky AJ**, McLaurin BT, Cox DA, Cristea E, Fahy M, Stone GW. Implications of pre-procedural TIMI flow in patients with non ST-segment elevation acute coronary syndromes undergoing percutaneous coronary revascularization: insights from the ACUTY trial. *International Journal Of Cardiology* 2013, 167:727-32.
 334. Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS, Cao S, Theodoropoulos K, Cutlip DE, **Lansky AJ**, Stone GW. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). *JACC. Cardiovascular Interventions* 2013, 6:914-22.
 335. Ormiston J, Webster M, Stewart J, Vrolix M, Whitbourn R, Donohoe D, Knape C, **Lansky A**, Attizzani GF, Fitzgerald P, Kandzari DE, Wijns W. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries). *JACC. Cardiovascular Interventions* 2013, 6:1026-34.

336. Buysschaert I, Dubois CL, Dens J, Ormiston J, Worthley S, McClean D, Ottervanger JP, Meredith I, Uren N, Wijns W, Whitbourn R, Mehran R, **Lansky AJ**, Bichalska M, Meis S, Verheye S. Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2013, 9:573-81.
337. Meier P, Franzen O, **Lansky AJ**. Almanac 2013: novel non-coronary cardiac interventions. *Anadolu Kardiyoloji Dergisi : AKD = The Anatolian Journal Of Cardiology* 2013, 13:622-31.
338. Brener SJ, Dizon JM, Mehran R, Guerchicoff A, **Lansky AJ**, Farkouh M, Brodie B, Guagliumi G, Witzensbichler B, Fahy M, Parise H, Stone GW. Complementary prognostic utility of myocardial blush grade and ST-segment resolution after primary percutaneous coronary intervention: analysis from the HORIZONS-AMI trial. *American Heart Journal* 2013, 166:676-83.
339. Dudek D, Mehran R, Dziewierz A, Brener SJ, Rakowski T, Brzezinski M, Brodie BR, Xu K, Fahy M, **Lansky AJ**, Zmudka K, Stone GW. Impact of bifurcation target lesion on angiographic, electrocardiographic, and clinical outcomes of patients undergoing primary percutaneous coronary intervention (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial). *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2013, 9:817-23.
340. Meier P, Franzen O, **Lansky AJ**. Almanac 2013: novel non-coronary cardiac interventions. *Wiener Klinische Wochenschrift* 2013, 125:766-75.
341. Stavropoulos SW, Sing RF, Elmasri F, Silver MJ, Powell A, Lynch FC, Aal AK, **Lansky AJ**, Settlage RA, Muhs BE. The DENALI Trial: an interim analysis of a prospective, multicenter study of the Denali retrievable inferior vena cava filter. *Journal Of Vascular And Interventional Radiology : JVIR* 2014, 25:1497-505, 1505.e1.
342. Meier P, **Lansky AJ**, Baumbach A. Almanac 2013: acute coronary syndromes. *Wiener Klinische Wochenschrift* 2014, 126:176-83.
343. Meier P, **Lansky AJ**, Baumbach A. Almanac 2013: acute coronary syndromes. *Anadolu Kardiyoloji Dergisi : AKD = The Anatolian Journal Of Cardiology* 2014.
344. Behan MW, **Lansky AJ**, Jolly S, Baumbach A. Will this trial change my practice? TASTE - a randomised registry on thrombus aspiration in primary PCI with a 30-day endpoint. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2014, 10:406-7.
345. Toth GG, Kala P, **Lansky A**, Baumbach A. Will this trial change my practice? PRAMI - treatment of bystander coronary lesions in patients undergoing primary PCI for acute STEMI. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2014, 10:411-2.
346. Meller SM, Baumbach A, Brickman AM, **Lansky AJ**. Clinical implications for diffusion-weighted MRI brain lesions associated with transcatheter aortic valve replacement. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2014, 83:502-8.
347. Meier P, **Lansky AJ**, Baumbach A. Almanac 2013: Acute coronary syndromes. *Acta Cardiologica* 2014, 69:100-8.
348. Bucholz EM, Butala NM, Rathore SS, Dreyer RP, **Lansky AJ**, Krumholz HM. Sex differences in long-term mortality after myocardial infarction: a systematic review. *Circulation* 2014, 130:757-67.

349. Ng VG, **Lansky AJ**, Meller S, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie B, Shah R, Mehran R, Stone GW. The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. *European Heart Journal. Acute Cardiovascular Care* 2014, 3:67-77.
350. **Lansky AJ**, Ng VG, Meller S, Xu K, Fahy M, Feit F, Ohman EM, White HD, Mehran R, Bertrand ME, Desmet W, Hamon M, Stone GW. Impact of nonculprit vessel myocardial perfusion on outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes: analysis from the ACUTY trial (Acute Catheterization and Urgent Intervention Triage Strategy). *JACC. Cardiovascular Interventions* 2014, 7:266-75.
351. Navarese EP, Kowalewski M, Kandzari D, **Lansky A**, Górny B, Kołtowski L, Waksman R, Berti S, Musumeci G, Limbruno U, van der Schaaf RJ, Kelm M, Kubica J, Suryapranata H. First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients. *Open Heart* 2014, 1:e000064.
352. Wolfrum M, Froehlich GM, Knapp G, Casaubon LK, DiNicolantonio JJ, **Lansky AJ**, Meier P. Stroke prevention by percutaneous closure of patent foramen ovale: a systematic review and meta-analysis. *Heart (British Cardiac Society)* 2014, 100:389-95.
353. Caixeta A, G  n  reux P, Palmerini T, **Lansky AJ**, Mehran R, Dangas GD, Xu K, Brener SJ, Stone GW. Prognostic utility of the SYNTAX score in patients with single versus multivessel disease undergoing percutaneous coronary intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy [ACUTY] trial). *The American Journal Of Cardiology* 2014, 113:203-10.
354. Meier P, **Lansky AJ**, Fahy M, Xu K, White HD, Bertrand ME, Mehran R, Stone GW. The impact of the coronary collateral circulation on outcomes in patients with acute coronary syndromes: results from the ACUTY trial. *Heart (British Cardiac Society)* 2014, 100:647-51.
355. G  n  reux P, Madhavan MV, Mintz GS, Maehara A, Kirtane AJ, Palmerini T, Tarigopula M, McAndrew T, **Lansky AJ**, Mehran R, Brener SJ, Stone GW. Relation between coronary calcium and major bleeding after percutaneous coronary intervention in acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy and Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trials). *The American Journal Of Cardiology* 2014, 113:930-5.
356. G  n  reux P, Madhavan MV, Mintz GS, Maehara A, Palmerini T, Lasalle L, Xu K, McAndrew T, Kirtane A, **Lansky AJ**, Brener SJ, Mehran R, Stone GW. Ischemic outcomes after coronary intervention of calcified vessels in acute coronary syndromes. Pooled analysis from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) and ACUTY (Acute Catheterization and Urgent Intervention Triage Strategy) TRIALS. *Journal Of The American College Of Cardiology* 2014, 63:1845-54.
357. Fr  hlich GM, **Lansky AJ**, Webb J, Roffi M, Toggweiler S, Reinthaler M, Wang D, Hutchinson N, Wendler O, Hildick-Smith D, Meier P. Local versus general anesthesia for transcatheter aortic valve implantation (TAVI)--systematic review and meta-analysis. *BMC Medicine* 2014, 12:41.
358. Navarese EP, Kowalewski M, Cortese B, Kandzari D, Dias S, Wojakowski W, Buffon A, **Lansky A**, Angelini P, Torguson R, Kubica J, Kelm M, de Boer MJ, Waksman R, Suryapranata H. Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients. *Atherosclerosis* 2014, 233:224-31.

359. Robertson JO, Ebrahimi R, **Lansky AJ**, Mehran R, Stone GW, Lincoff AM. Impact of cigarette smoking on extent of coronary artery disease and prognosis of patients with non-ST-segment elevation acute coronary syndromes: an analysis from the ACUITY Trial (Acute Catheterization and Urgent Intervention Triage Strategy). *JACC. Cardiovascular Interventions* 2014, 7:372-9.
360. Meier P, Franzen O, **Lansky AJ**. Almanac 2013: novel non-coronary cardiac interventions. *Türk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir* 2014, 42:203-15.
361. Litsky J, Chanda A, Stilp E, **Lansky A**, Mena C. Critical evaluation of stents in the peripheral arterial disease of the superficial femoral artery - focus on the paclitaxel eluting stent. *Medical Devices (Auckland, N.Z.)* 2014, 7:149-56.
362. Kelly CR, Weisz G, Maehara A, Mintz GS, Mehran R, **Lansky AJ**, Parise H, de Bruyne B, Serruys PW, Stone GW. Relation of C-reactive protein levels to instability of untreated vulnerable coronary plaques (from the PROSPECT Study). *The American Journal Of Cardiology* 2014, 114:376-83.
363. **Lansky AJ**, Pietras C. Fractional flow reserve from 3-dimensional quantitative coronary angiography: fresh light through an old window. *JACC. Cardiovascular Interventions* 2014, 7:778-80.
364. Meier P, Franzen O, **Lansky AJ**. Almanac 2013: novel non-coronary cardiac interventions. *Acta Cardiologica* 2014, 69:435-45.
365. Dangas GD, Farkouh ME, Sleeper LA, Yang M, Schoos MM, Macaya C, Abizaid A, Buller CE, Devlin G, Rodriguez AE, **Lansky AJ**, Siami FS, Domanski M, Fuster V. Long-term outcome of PCI versus CABG in insulin and non-insulin-treated diabetic patients: results from the FREEDOM trial. *Journal Of The American College Of Cardiology* 2014, 64:1189-97.
366. Goto K, **Lansky AJ**, Ng VG, Pietras C, Nargileci E, Mehran R, Parise H, Feit F, Ohman EM, White HD, Bertrand ME, Desmet W, Hamon M, Stone GW. Prognostic value of angiographic lesion complexity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the acute catheterization and urgent intervention triage strategy trial). *The American Journal Of Cardiology* 2014, 114:1638-45.
367. Majidi M, Kosinski AS, Al-Khatib SM, Smolders L, Cristea E, **Lansky AJ**, Stone GW, Mehran R, Gibbons RJ, Crijns HJ, Wellens HJ, Gorgels AP, Krucoff MW. Implications of ventricular arrhythmia "bursts" with normal epicardial flow, myocardial blush, and ST-segment recovery in anterior ST-elevation myocardial infarction reperfusion: a biosignature of direct myocellular injury "downstream of downstream". *European Heart Journal. Acute Cardiovascular Care* 2015, 4:51-9.
368. Prasad A, Gersh BJ, Mehran R, Brodie BR, Brener SJ, Dizon JM, **Lansky AJ**, Witzensichler B, Kornowski R, Guagliumi G, Dudek D, Stone GW. Effect of Ischemia Duration and Door-to-Balloon Time on Myocardial Perfusion in ST-Segment Elevation Myocardial Infarction: An Analysis From HORIZONS-AMI Trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction). *JACC. Cardiovascular Interventions* 2015, 8:1966-1974.
369. Wijns W, Vrolix M, Verheye S, Schoors D, Slagboom T, Gosselink M, Benit E, Donohoe D, Knappe C, Attizzani GF, **Lansky AJ**, Ormiston J. Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: results of the DESSOLVE II trial. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2015, 10:1383-90.
370. **Lansky AJ**, Pietras C. Coronary Microvascular Dysfunction: Does Sex Matter? *JACC. Cardiovascular Interventions* 2015, 8:1442-4.

371. Clarke JL, Ladapo JL, Monane M, **Lansky A**, Skoufalos A, Nash DB. The diagnosis of CAD in women: addressing the unmet need - a report from the national expert roundtable meeting. *Population Health Management* 2015, 18:86-92.
372. Souza CF, Doi H, Mintz GS, **Lansky AJ**, Witzienbichler B, Guagliumi G, Brodie BR, Kellett MA, Xu K, Mehran R, Stone GW, Maehara A. Morphological changes and clinical impact of unstable plaques within untreated segments of acute myocardial infarction patients during a 3-year follow-up: an analysis from the HORIZONS-AMI trial. *Coronary Artery Disease* 2015, 26:469-75.
373. Spatz ES, Curry LA, Masoudi FA, Zhou S, Strait KM, Gross CP, Curtis JP, **Lansky AJ**, Soares Barreto-Filho JA, Lampropoulos JF, Bueno H, Chaudhry SI, D'Onofrio G, Safdar B, Dreyer RP, Murugiah K, Spertus JA, Krumholz HM. The Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients (VIRGO) Classification System: A Taxonomy for Young Women With Acute Myocardial Infarction. *Circulation* 2015, 132:1710-8.
374. Baumbach A, Mullen M, Brickman AM, Aggarwal SK, Pietras CG, Forrest JK, Hildick-Smith D, Meller SM, Gambone L, den Heijer P, Margolis P, Voros S, **Lansky AJ**. Safety and performance of a novel embolic deflection device in patients undergoing transcatheter aortic valve replacement: results from the DEFLECT I study. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2015, 11:75-84.
375. Gao Z, Zhang R, Xu B, Yang Y, Ma C, Li H, Chen S, Han Y, Yuan Z, **Lansky AJ**, Guan C, Leon MB, Gao R. Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: two-year results from a prospective patient-level pooled analysis of TARGET trials. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2015, 85 Suppl 1:734-43.
376. Rusinaru D, Vrolix M, Verheye S, Chowdhary S, Schoors D, Di Mario C, Desmet W, Donohoe DJ, Ormiston JA, Knape C, Bezerra H, **Lansky A**, Wijns W. Bioabsorbable polymer-coated sirolimus-eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial sub-study. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2015, 86:1141-50.
377. Grundeken MJ, **Lansky A**, Tanguay JF, Gershlick A, Baumbach A, Cuisset T. Will this trial change my practice? The Dual Antiplatelet Therapy (DAPT) study - 12 or 30 months of dual antiplatelet therapy after drug-eluting stents. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2015, 11:364-5.
378. Ng VG, Mena C, Pietras C, **Lansky AJ**. Local delivery of paclitaxel in the treatment of peripheral arterial disease. *European Journal Of Clinical Investigation* 2015, 45:333-45.
379. **Lansky AJ**, Schofer J, Tchetché D, Stella P, Pietras CG, Parise H, Abrams K, Forrest JK, Cleman M, Reinöhl J, Cuisset T, Blackman D, Bolotin G, Spitzer S, Kappert U, Gilard M, Modine T, Hildick-Smith D, Haude M, Margolis P, Brickman AM, Voros S, Baumbach A. A prospective randomized evaluation of the TriGuard™ HDH embolic DEFLECTION device during transcatheter aortic valve implantation: results from the DEFLECT III trial. *European Heart Journal* 2015, 36:2070-2078.
380. Behan MW, Haude M, Oldroyd KG, **Lansky AJ**, James S, Baumbach A. Will this trial change my practice? TOTAL: a randomised trial of thrombus aspiration in ST-elevation myocardial infarction. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2015, 11:361-3.

381. Baumbach A, Pietras C, **Lansky A**. The TriGuard embolic deflection device for prevention of stroke and cerebral embolization during transcatheter aortic valve replacement. *Expert Review Of Medical Devices* 2015, 12:649-51.
382. Van Gils L, Baumbach A, Himbert D, **Lansky AJ**, Vahanian A, Van Mieghem NM. Tools and Techniques - Clinical: Embolic protection devices in transcatheter aortic valve implantation. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2015, 11:247-8.
383. Hassanin A, Brener SJ, **Lansky AJ**, Xu K, Stone GW. Prognostic impact of multivessel versus culprit vessel only percutaneous intervention for patients with multivessel coronary artery disease presenting with acute coronary syndrome. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2015, 11:293-300.
384. Yu J, Mehran R, Grinfeld L, Xu K, Nikolsky E, Brodie BR, Witzenbichler B, Kornowski R, Dangas GD, **Lansky AJ**, Stone GW. Sex-based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: three year results from the HORIZONS-AMI trial. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2015, 85:359-68.
385. **Lansky AJ**, Ng VG. What the Clinical Event Committee Does Not See When It Comes to Stent Thrombosis. *Circulation. Cardiovascular Interventions* 2016, 9:e003861.
386. **Lansky AJ**, Kastrati A, Edelman ER, Parise H, Ng VG, Ormiston J, Wijns W, Byrne RA. Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies). *The American Journal Of Cardiology* 2016, 117:532-538.
387. Ng VG, Baumbach A, Grinfeld L, Lincoff AM, Mehran R, Stone GW, **Lansky AJ**. Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUTY, and HORIZONS-AMI Trials). *The American Journal Of Cardiology* 2016, 117:186-91.
388. Tu S, Westra J, Yang J, von Birgelen C, Ferrara A, Pellicano M, Nef H, Tebaldi M, Murasato Y, **Lansky A**, Barbato E, van der Heijden LC, Reiber JH, Holm NR, Wijns W. Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography: The International Multicenter FAVOR Pilot Study. *JACC. Cardiovascular Interventions* 2016, 9:2024-2035.
389. Giustino G, Mehran R, Bansilal S, Feit F, Lincoff M, Deliargyris EN, Kirtane AJ, G  n  reux P, Redfors B, Prats J, Bernstein D, Brener SJ, Skerjanec S, **Lansky AJ**, Francese DP, Dangas GD, Stone GW. Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUTY and HORIZONS-AMI Trials. *The American Journal Of Cardiology* 2016, 118:6-16.
390. **Lansky AJ**, Brown D, Pena C, Pietras CG, Parise H, Ng VG, Meller S, Abrams KJ, Cleman M, Margolis P, Petrossian G, Brickman AM, Voros S, Moses J, Forrest JK. Neurologic Complications of Unprotected Transcatheter Aortic Valve Implantation (from the Neuro-TAVI Trial). *The American Journal Of Cardiology* 2016, 118:1519-1526.
391. I  iguez A, Brener SJ, Jim  nez VA, Maehara A, Mintz GS, Xu K, Weisz G, **Lansky AJ**, De Bruyne B, Serruys PW, Stone GW. Significance of prior percutaneous revascularisation in patients with acute coronary syndromes: insights from the prospective PROSPECT registry. *EuroIntervention : Journal*

- Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology 2016, 11:1468-74.
392. Forrest JK, Adams DH, Popma JJ, Reardon MJ, Deeb GM, Yakubov SJ, Hermiller JB, Huang J, Skelding KA, **Lansky A**. Transcatheter Aortic Valve Replacement in Women Versus Men (from the US CoreValve Trials). The American Journal Of Cardiology 2016, 118:396-402.
 393. Goto K, Mintz GS, Litherland C, **Lansky AJ**, Weisz G, McPherson JA, De Bruyne B, Serruys PW, Stone GW, Maehara A. Lumen Measurements From Quantitative Coronary Angiography and IVUS: A PROSPECT Substudy. JACC. Cardiovascular Imaging 2016, 9:1011-3.
 394. Stavropoulos SW, Chen JX, Sing RF, Elmasri F, Silver MJ, Powell A, Lynch FC, Abdel Aal AK, **Lansky A**, Muhs BE. Analysis of the Final DENALI Trial Data: A Prospective, Multicenter Study of the Denali Inferior Vena Cava Filter. Journal Of Vascular And Interventional Radiology : JVIR 2016, 27:1531-1538.e1.
 395. Ng VG, Mori K, Costa RA, Kish M, Mehran R, Urata H, Saku K, Stone GW, **Lansky AJ**. Impact of gender on infarct size, ST-segment resolution, myocardial blush and clinical outcomes after primary stenting for acute myocardial infarction: Substudy from the EMERALD trial. International Journal Of Cardiology 2016, 207:269-76.
 396. Brener SJ, Mehran R, **Lansky AJ**, Ayele GM, Stone GW. Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials. European Heart Journal. Acute Cardiovascular Care 2016, 5:449-54.
 397. Ng VG, **Lansky AJ**, Toro S, Parise H, Cristea E, Mehran R, Stone GW. Prognostic utility of myocardial blush grade after PCI in patients with NSTEMI-ACS: Analysis from the ACUITY trial. Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions 2016, 88:215-24.
 398. Ng VG, **Lansky AJ**. Controversies in the Treatment of Women with ST-Segment Elevation Myocardial Infarction. Interventional Cardiology Clinics 2016, 5:523-532.
 399. Collet C, Onuma Y, Cavalcante R, Grundeken M, G  n  reux P, Popma J, Costa R, Stankovic G, Tu S, Reiber JHC, Aben JP, Lassen JF, Louvard Y, **Lansky A**, Serruys PW. Quantitative angiography methods for bifurcation lesions: a consensus statement update from the European Bifurcation Club. EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology 2017, 13:115-123.
 400. Bouras G, Jhamnani S, Ng VG, Haimi I, Mao V, Deible R, Cao S, Sudhir K, **Lansky AJ**. Clinical outcomes after PCI treatment of very long lesions with the XIENCE V everolimus eluting stent; Pooled analysis from the SPIRIT and XIENCE V USA prospective multicenter trials. Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions 2017, 89:984-991.
 401. Mehta S, Granger CB, Henry TD, Grines CL, **Lansky A**, Rokos I, Botelho R, Baumbach A, Mishra S, Cheem TH, Tresukosol D, Zambahari R, Ferr   A, Castillo M. Reducing system delays in treatment of ST elevation myocardial infarction and confronting the challenges of late presentation in low and middle-income countries. Indian Heart Journal 2017, 69 Suppl 1:S1-S5.
 402. Brodmann M, Werner M, Brinton TJ, Illindala U, **Lansky A**, Jaff MR, Holden A. Safety and Performance of Lithoplasty for Treatment of Calcified Peripheral Artery Lesions. Journal Of The American College Of Cardiology 2017, 70:908-910.
 403. Kuijt WJ, Green CL, Verouden NJW, Haeck JDE, Tzivoni D, Koch KT, Stone GW, **Lansky AJ**, Broderick S, Tijssen JGP, de Winter RJ, Roe MT, Krucoff MW. What is the best ST-segment recovery

- parameter to predict clinical outcome and myocardial infarct size? Amplitude, speed, and completeness of ST-segment recovery after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. *Journal Of Electrocardiology* 2017, 50:952-959.
404. Kedhi E, Kennedy MW, Maehara A, **Lansky AJ**, McAndrew TC, Marso SP, De Bruyne B, Serruys PW, Stone GW. Impact of TCFA on Unanticipated Ischemic Events in Medically Treated Diabetes Mellitus: Insights From the PROSPECT Study. *JACC. Cardiovascular Imaging* 2017, 10:451-458.
 405. Jones DA, Tchéché D, Forrest J, Hellig F, **Lansky A**, Moat N. The SURTAVI study: TAVI for patients with intermediate risk. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2017, 13:e617-e620.
 406. **Lansky AJ**, Messé SR, Brickman AM, Dwyer M, van der Worp HB, Lazar RM, Pietras CG, Abrams KJ, McFadden E, Petersen NH, Browndyke J, Prendergast B, Ng VG, Cutlip DE, Kapadia S, Krucoff MW, Linke A, Moy CS, Schofer J, van Es GA, Virmani R, Popma J, Parides MK, Kodali S, Bilello M, Zivadinov R, Akar J, Furie KL, Gress D, Voros S, Moses J, Greer D, Forrest JK, Holmes D, Kappetein AP, Mack M, Baumbach A. Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative. *Journal Of The American College Of Cardiology* 2017, 69:679-691.
 407. Mangiacapra F, Maeng M, Cayla G, **Lansky A**, Meier P, Kolh P. EXCEL and NOBLE: stents or surgery for left main stem stenosis? *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2017, 13:e604-e608.
 408. Kitahara H, Okada K, Kimura T, Yock PG, **Lansky AJ**, Popma JJ, Yeung AC, Fitzgerald PJ, Honda Y. Impact of Stent Size Selection on Acute and Long-Term Outcomes After Drug-Eluting Stent Implantation in De Novo Coronary Lesions. *Circulation. Cardiovascular Interventions* 2017, 10.
 409. Ukena C, Leonardi S, Palmerini T, **Lansky A**, Montalescot G, Valgimigli M. Will PIONEER AF-PCI change my practice? *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2017, 13:e609-e612.
 410. Laird JR, Zeller T, Loewe C, Chamberlin J, Begg R, Schneider PA, Nanjundappa A, Bunch F, Schultz S, Harlin S, **Lansky A**, Jaff MR. Novel Nitinol Stent for Lesions up to 24 cm in the Superficial Femoral and Proximal Popliteal Arteries: 24-Month Results From the TIGRIS Randomized Trial. *Journal Of Endovascular Therapy : An Official Journal Of The International Society Of Endovascular Specialists* 2018, 25:68-78.
 411. Pagnesi M, Regazzoli D, Ancona MB, Mangieri A, Lanzillo G, Giannini F, Buzzatti N, Prendergast BD, Kodali S, **Lansky AJ**, Colombo A, Latib A. Cerebral Embolic Risk During Transcatheter Mitral Valve Interventions: An Unaddressed and Unmet Clinical Need? *JACC. Cardiovascular Interventions* 2018, 11:517-528.
 412. Baumbach A, Zaman A, West NE, O'Kane P, Egred M, Johnson T, Wheatcroft S, Ruth B, de Belder A, Bouras G, **Lansky A**, Hill J, Mathur A, de Belder MA, Banning A. Acute and one-year clinical outcomes following implantation of bioresorbable vascular scaffolds: the ABSORB UK Registry. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2018, 13:1554-1560.
 413. Stone PH, Maehara A, Coskun AU, Maynard CC, Zaromytidou M, Siasos G, Andreou I, Fotiadis D, Stefanou K, Papafakis M, Michalis L, **Lansky AJ**, Mintz GS, Serruys PW, Feldman CL, Stone GW. Role of Low Endothelial Shear Stress and Plaque Characteristics in the Prediction of Nonculprit Major Adverse Cardiac Events: The PROSPECT Study. *JACC. Cardiovascular Imaging* 2018, 11:462-471.

414. **Lansky AJ**, Messé SR, Brickman AM, Dwyer M, Bart van der Worp H, Lazar RM, Pietras CG, Abrams KJ, McFadden E, Petersen NH, Browndyke J, Prendergast B, Ng VG, Cutlip DE, Kapadia S, Krucoff MW, Linke A, Scala Moy C, Schofer J, van Es GA, Virmani R, Popma J, Parides MK, Kodali S, Bilello M, Zivadinov R, Akar J, Furie KL, Gress D, Voros S, Moses J, Greer D, Forrest JK, Holmes D, Kappetein AP, Mack M, Baumbach A. Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative. *European Heart Journal* 2018, 39:1687-1697.
415. Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Thanh Hai MT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, **Lansky AJ**, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. *Journal Of The American College Of Cardiology* 2018, 71:1021-1034.
416. Zhang H, Mu L, Hu S, Nallamothu BK, **Lansky AJ**, Xu B, Bouras G, Cohen DJ, Spertus JA, Masoudi FA, Curtis JP, Gao R, Ge J, Yang Y, Li J, Li X, Zheng X, Li Y, Krumholz HM, Jiang L. Comparison of Physician Visual Assessment With Quantitative Coronary Angiography in Assessment of Stenosis Severity in China. *JAMA Internal Medicine* 2018, 178:239-247.
417. Mehta S, Granger C, Grines CL, Jacobs A, Henry TD, Rokos I, **Lansky A**, Baumbach A, Botelho R, Ferre A, Yepes I, Salwan R, Dalal J, Makkar J, Bhalla N, Mishra S, Vijan V, Hiremath S. Confronting system barriers for ST- elevation MI in low and middle income countries with a focus on India. *Indian Heart Journal* 2018, 70:185-190.
418. Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Hai MTT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, **Lansky AJ**, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. *Circulation* 2018, 137:961-972.
419. Michael TT, Richardt G, **Lansky A**, Carney RJ, Khan MA, Shehadeh A, Zeymer U, Gupta S. Nine-month results of the BIOHELIX-I clinical trial study: Evaluation of the PRO-Kinetic Energy cobalt chromium bare-metal stent system. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2018, 92:1030-1039.
420. Serrao GW, **Lansky AJ**, Mehran R, Stone GW. Predictors of Left Ventricular Ejection Fraction Improvement After Primary Stenting in ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). *The American Journal Of Cardiology* 2018, 121:678-683.
421. Mustapha JA, **Lansky A**, Shishehbor M, Miles McClure J, Johnson S, Davis T, Makam P, Crowder W, Konstantino E, Attaran RR. A prospective, multi-center study of the chocolate balloon in femoropopliteal peripheral artery disease: The Chocolate BAR registry. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2018, 91:1144-1148.
422. Gul B, Kozuma K, Haimi I, Zhao W, Simonton C, Ying SW, Buda A, Mehta S, Baumbach A, **Lansky A**. Sex disparities in acute myocardial infarction care and outcomes. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2018, 92:E341-E347.

423. **Lansky A**, Ghare MI, Tchétché D, Baumbach A. TAVI and the brain: update on definitions, evidence of neuroprotection and adjunctive pharmacotherapy. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2018, 14:AB53-AB63.
424. **Lansky A**, Wijns W, Xu B, Kelbæk H, van Royen N, Zheng M, Morel MA, Knaapen P, Slagboom T, Johnson TW, Vlachoianis G, Arkenbout KE, Holmvang L, Janssens L, Ochala A, Brugaletta S, Naber CK, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina C, Buszman P, Thiele H, Schächinger V, Baumbach A. Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial. *Lancet* 2018, 392:1117-1126.
425. **Lansky AJ**, Ghare MI, Pietras C. Carotid Disease and Stroke After Transcatheter Aortic Valve Replacement. *Circulation. Cardiovascular Interventions* 2018, 11:e006826.
426. Baumbach A, **Lansky AJ**, Onuma Y, Asano T, Johnson T, Anderson R, Kiemeneij F, Zheng M, Van Royen N, Slagboom T, Vlachoianis G, Xu B, Serruys P, Wijns W. Optical coherence tomography substudy of a prospective multicentre randomised post-market trial to assess the safety and effectiveness of the Firehawk cobalt-chromium coronary stent (rapamycin target-eluting) system for the treatment of atherosclerotic lesions: TARGET All Comers. *EuroIntervention : Journal Of EuroPCR In Collaboration With The Working Group On Interventional Cardiology Of The European Society Of Cardiology* 2018, 14:1121-1128.
427. Brodmann M, Werner M, Holden A, Tepe G, Scheinert D, Schwindt A, Wolf F, Jaff M, **Lansky A**, Zeller T. Primary outcomes and mechanism of action of intravascular lithotripsy in calcified, femoropopliteal lesions: Results of Disrupt PAD II. *Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions* 2019, 93:335-342.
428. Gul B, **Lansky A**, Budoff MJ, Sharp D, Maniet B, Herman L, Kuo JZ, Huang L, Monane M, Ladapo JA. The Clinical Utility of a Precision Medicine Blood Test Incorporating Age, Sex, and Gene Expression for Evaluating Women with Stable Symptoms Suggestive of Obstructive Coronary Artery Disease: Analysis from the PRESET Registry. *Journal Of Women's Health (2002)* 2019, 28:728-735.
429. Ghare MI, Chandrasekhar J, Mehran R, Ng V, Grines C, **Lansky A**. Sex Disparities in Cardiovascular Device Evaluations: Strategies for Recruitment and Retention of Female Patients in Clinical Device Trials. *JACC. Cardiovascular Interventions* 2019, 12:301-308.
430. Brinton TJ, Ali ZA, Hill JM, Meredith IT, Maehara A, Illindala U, **Lansky A**, Götzberg M, Van Mieghem NM, Whitbourn R, Fajadet J, Di Mario C. Feasibility of Shockwave Coronary Intravascular Lithotripsy for the Treatment of Calcified Coronary Stenoses. *Circulation* 2019, 139:834-836.
431. Laird JR, Zeller T, Holden A, Scheinert D, Moore E, Mendes R, Schmiedel R, Settlege R, **Lansky A**, Jaff MR. Balloon-Expandable Vascular Covered Stent in the Treatment of Iliac Artery Occlusive Disease: 9-Month Results from the BOLSTER Multicenter Study. *Journal Of Vascular And Interventional Radiology : JVIR* 2019, 30:836-844.e1.
432. Xu B, Saito Y, Baumbach A, Kelbæk H, van Royen N, Zheng M, Morel MA, Knaapen P, Slagboom T, Johnson TW, Vlachoianis G, Arkenbout KE, Holmvang L, Janssens L, Ochala A, Brugaletta S, Naber CK, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina C, Buszman P, Thiele H, Schächinger V, **Lansky A**, Wijns W. 2-Year Clinical Outcomes of an Abluminal Groove-Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent. *JACC. Cardiovascular Interventions* 2019.

433. Attaran RR, Ozdemir D, Lin IH, Mena-Hurtado C, **Lansky A**. Evaluation of anticoagulant and antiplatelet therapy after ilio caval stenting: Factors associated with stent occlusion. Journal Of Vascular Surgery. Venous And Lymphatic Disorders 2019, 7:527-534.